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Abstract 
 
Introduction: Sphingosine 1 phosphate (S1P) is a major constituent of high density 
lipoprotein (HDL) cholesterol. Both S1P preconditioning and ischaemic 
postconditioning reduce myocardial damage following an ischaemia-reperfusion 
insult but the mechanisms involved remain unclear. Janus kinase/Signal transducer 
and activator of transcription 3 (JAK/STAT-3) form part of a recently discovered 
powerful prosurvival path termed as the Survivor Activating Factor Enhancement 
(SAFE) pathway. The SAFE pathway plays a critical role in ischaemic 
preconditioning to promote cell survival but whether activation of STAT-3 is required 
for S1P preconditioning and ischaemic postconditioning induced cardioprotection is 
unknown. 
 
Hypothesis: Activation of the STAT-3 is required for S1P preconditioning and 
ischaemic postconditioning. 
 
Methods: Mouse fibroblast L-cells were cultured and subjected to 8.5 hours of 
simulated ischaemia. Cells were preconditioned for 30 minutes with S1P with/without 
AG490, a STAT-3 pathway inhibitor. Isolated hearts from male Wistar rats were 
subjected to ischaemia-reperfusion, and preconditioned with a 7 minute episode of 
S1P with/without AG490. Hearts undergoing ischaemic postconditioning were 
subjected to 30 minutes of ischaemia followed by 6 cycles of intermittent 10 second 
cycles of ischaemia reperfusion at the onset of reperfusion with/without AG490. Cell 
survival, haemodynamic parameters, functional parameters, infarct size and western 
blots analysis were assessed as end points. 
 
Results: S1P preconditioning improved cell survival in fibroblasts subjected to 
simulated ischaemia (38.1±1.5% vs. 30.0±0.0%, p<0.05 vs. control), an effect 
abolished in the presence of AG490 (29.9±2.7%, ns vs. control). S1P preconditioning 
also decreased infarct size (4.6±1.4% vs. 25.8±3.1%., p<0.05 vs. control), but this 
effect was abolished with AG490 (29.5±4.0%. ns vs. control). Similarly, ischaemic 
postconditioning decreased infarct size (11±1% vs. 32±5%., p<0.05 vs. control) but 
this infarct sparing effect was abolished with AG490 (26±4%, ns vs. control). Finally, 
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ischaemia postconditioning resulted in the concomitant decrease in the cytosolic 
fraction and increase in the nuclear fraction of tyrosine phosphorylated STAT-3 
(0.5±0.1A.U. vs. 1.6±0.3A.U., p<0.05 vs. control and 2.5±0.2A.U. vs. 1.3±0.4A.U., 
p<0.05 vs. control, respectively). 
 
Conclusion: Our data suggest that both S1P preconditioning and ischaemic 
postconditioning can protect the heart similar to ischaemic preconditioning. This 
protection requires the activation of STAT-3, therefore suggesting that activation of 
the SAFE pathway is critical to conditioning of the heart. Our findings may lead to the 
development of novel therapies to protect the heart against ischaemic heart disease. 
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Chapter One: Introduction 
 
Cardiovascular disease is projected to be the leading cause of global mortality in 
2020 according to the World Health Organisation (Murray and Lopez, 1997). South 
Africa is currently in a transitional state, burdened by the growing infectious diseases 
such as the HIV pandemic and emerging chronic diseases. Cardiovascular disease 
is the leading cause of chronic diseases and is currently the second most important 
cause of death in South Africa (Mayosi et al., 2009, Bradshaw et al., 2003) (Figure 
1).  
 
Figure 1: Mortality rate of the South African population due to cardiovascular 
disease 
Males (A) and females (B) aged 15-64 years old die from different causes of cardiovascular disease 
represented deaths per 100 000 population (Mayosi et al., 2009). 
 
The most prominent cardiovascular disease is coronary heart disease (Yusuf et al., 
2004). It refers to the accumulation of an atherosclerotic plaque in coronary arteries, 
resulting in either partial or total vessel obstruction. The obstruction results in a 
reduction of blood flow, nutrients and oxygen to the cardiac tissue distal to the 
obstruction. Should the obstruction continue, the cardiac tissue will progressively 
become ischaemic and place the ischaemic tissue at risk of cell death. Should no 
intervention take place to relieve the obstruction, the ischaemic tissue will undergo 
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irreversible cell death and hence would be referred to as having undergone infarction 
(Figure 2). 
 
 
Figure 2: Graphic representation of an acute myocardial infarction 
Patients with coronary artery disease can develop a blocked coronary artery, typically the result of 
atherosclerotic build up within the coronary with or without the addition of a thrombus (from 
www.adam.about.com/encyclopedia/acute.mi.html) 
The extent and severity of a myocardial infarct has long been known to prognosticate 
a patients outcome (Braunwald, 1974) and extensive research was focused on how 
to decrease the amount or size of myocardial infarction as a result of ischaemia.  
 
Early research indicated that the best intervention to salvage ischaemic cardiac 
tissue was to restore blood flow or reperfuse the ischaemic tissue (Maroko et al., 
1972). Clinically, reperfusion can be achieved with the use of thrombolytic drugs or 
by coronary balloon angioplasty (Vinten-Johansen et al., 2007). However, whilst 
reperfusion is overall beneficial, it does paradoxically lead to additional tissue 
damage, an effect known as ‘reperfusion injury’ (Murry et al., 1986). Reperfusion 
injury can account for up to 50% of the final infarcted tissue as a result of endothelial 
damage, arrhythmias and stunned myocardium (Yellon and Hausenloy, 2007).  
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1. Concept of conditioning 
1.1 Preconditioning versus postconditioning 
 
In 1986, Murray et al. discovered an intrinsic cardioprotective mechanism against 
reperfusion injury and called the phenomenon ‘ischaemic preconditioning’. It involved 
four cycles of five minutes of ischaemia with intermittent reperfusion prior to the main 
ischaemic insult. The result was a decrease in infarct size by 75% (Murry et al., 
1986).  
 
Brief repetitive episodes of ischaemia decreased the rate of adenosine triphosphate 
(ATP) depletion during subsequent ischaemic episodes (Reimer et al., 1986) and 
intermittently washed away many harmful metabolites such as lactate, hydrogen ions 
and ammonia (Murry et al., 1986). As a result, more cardiac tissue was salvaged 
which was reflected as a decrease in infarct size.  
 
Seventeen years later, Vinten-Johansen and colleagues (2003) discovered that 
similar cycles of ischaemia and intermittent reperfusion occurring after the main 
ischaemic insult, resulted in a similar decrease in infarct size as seen in ischaemic 
preconditioning. This new phenomenon was called ischaemic postconditioning (Zhao 
et al., 2003) (Figure 3). 
 
The protective effect of ischaemic postconditioning was hypothesized to be the result 
of delayed realkalinisation of the acidic ischaemic tissue, which in turn, delays the 
accumulation of intracellular calcium ions. Hence, ischaemic contractures due to 
intracellular calcium ion overload are avoided (Piper et al., 2003).  
 
Ischaemic preconditioning allows the heart to initiate not only protective mechanisms 
prior to ischaemia but also after ischaemia and hence during the reperfusion phase 
(Hausenloy et al., 2005). In contrast, postconditioning can only activate protective 
mechanisms at the onset of reperfusion (Crisostomo et al., 2006). Despite these 
differences, many signalling pathways have been found to be shared (Crisostomo et 
al., 2006, Vinten-Johansen et al., 2007, Hausenloy and Yellon, 2007).  
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Ischaemia/reperfusion 
 
 
Preconditioning 
 
 
Postconditioning 
 
Figure 3: Schematic representation of preconditioning and postconditioning 
Standard ischaemia reperfusion protocol involved 30 minutes of stabilisation, followed by 30 minutes 
of index ischaemia and reperfusion for 2 hours. Preconditioning prot col involved 2 cycles of 5 
minutes of ischaemia and reperfusion followed by 10 minutes of reperfusion.  Postconditioning 
involved 6 cycles of ischaemia and reperfusion for 10 seconds each. 
 
1.2 Classical versus delayed conditioning 
 
Classical preconditioning or the first window of protection has been discussed and 
refers to the initial phase of protection from ischaemia. It is robust and lasts between 
one and two hours after the main ischaemic event. Delayed or the second window of 
protection refers to the period in which protection from ischaemia can occur 24 hours 
after the main ischaemic event, lasting between 48-72 hours (Bolli et al., 2007) 
(Figure 4). 
 
Ischaemia Reperfusion Stabilisation 
Reperfusion  Stabilisation  Ischaemia  
Ischaemia  Reperfusion  Stabilisation  
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Figure 4: Schematic diagram showing two phases of protection from 
ischaemia 
The classical preconditioning occurring early lasting 2 to 4 hours. The delayed phase occurring only 
24 to 48 hours later and lasting 3 to 4 days (Marber et al., 1993).  
 
There are important distinctions between classical and delayed preconditioning 
mechanisms. The former is the result of immediate change of pre-existing proteins 
whilst the latter involves newly synthesized proteins. As a result, the former only 
limits the progression of the final infarct size while the latter will also preserve the 
functional capacity of the myocardium (Bolli et al., 2007).  
 
Similar to classical preconditioning, classical postconditioning requires intermittent 
episodes of ischaemia to be applied ideally immediately after the onset of 
reperfusion or postponed until up to one minute after reperfusion. Thereafter, 
protection from postconditioning was lost (Kin et al., 2004).  
 
Delayed postconditioning has been sparsely explored in the heart with a few studies 
in the brain. Delayed postconditioning has been found to be effective in the brain 
following an episode of a stroke three to six hours after the main ischaemic event 
(Ren et al., 2008, Berdeaux, 2007, Ren et al., 2009). 
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1.3 Pharmacological conditioning 
 
Certain pharmacological compounds can substitute ischaemia as triggers for 
preconditioning like protection (Bolli, 2001). Such pharmacological compounds allow 
easier clinical application via medical rather than surgical methods (Granfeldt et al., 
2009). Many of these pharmacological compounds mimic the innate production of 
compounds that otherwise would have been produced as a result of ischaemic 
preconditioning. 
 
Compounds that can imitate preconditioning include adenosine (Liu et al., 1991), 
bradykinin (Goto et al., 1995), opioid agonists (Schultz et al., 1995), ethanol (Krenz 
et al., 2001), atrial naturetic peptide (ANP) (Okawa et al., 2003), cyclosporine (Yang 
et al., 2003), nicorandial (Mizumura et al., 1997),  statins (Jones and Lefer, 2001) 
and tumour necrosis factor alpha (TNFα) (Lecour et al., 2002).  
 
Since many signalling pathways are shared between preconditioning and 
postconditioning, not surprisingly many of these compounds can initiate 
postconditioning. These include adenosine (Yang et al., 2005) , bradykinin (Penna et 
al., 2007), opioid agonists (Zatta et al., 2008), ANP (Takagi et al., 2000), 
cyclosporine (Argaud et al., 2005a) and TNFα (Lacerda et al., 2009). Statins 
however have not been found to not be effective in postconditioning (Kocsis et al., 
2008). 
 
1.4 Remote conditioning 
1.4.1 Remote preconditioning 
 
In 1993, Pryzyklenk demonstrated that ischaemic preconditioning in one region of 
the heart conferred protection to another region of the heart. Both regions were 
distinct in their different blood supply and the modified form of preconditioning was 
called remote preconditioning (Przyklenk et al., 1993).  
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Subsequently, it was shown that preconditioning other organs conferred protection to 
heart. These other organs include skeletal muscle (Addison et al., 2003), intestine 
(Gho et al., 1996) and kidney (Pell et al., 1998). 
 
Whilst the mechanism of action of remote preconditioning is almost identical to 
ischaemic preconditioning, there are three hypotheses regarding the communication 
of remote ischaemia to protect other organs. The first hypothesis is the neuronal 
hypothesis where local release of adenosine and bradykinin can stimulate local 
nerve endings to signal other organs via neuronal signals. The second hypothesis is 
the humoral hypothesis where local release of adenosine and bradykinin can be 
released into the blood stream for systemic signalling. The third hypothesis is the 
‘inflammatory suppression hypothesis’ in which a systemic anti-inflammatory and 
anti-apoptotic phenotype is induced resulting in protection. It is likely that all three 
hypotheses play a role, however the mechanisms involved are still unclear 
(Hausenloy and Yellon, 2008). 
 
1.4.2  Remote postconditioning 
 
Application of ischaemia in remote postconditioning is similar to remote 
preconditioning but it can occur during two time points. The first is referred to as 
‘perconditioning’ whereby ischaemic postconditioning is applied to the remote organ 
during myocardial ischaemia (Kerendi et al., 2005). The second refers to the 
traditional sense of ischaemic postconditioning where intermittent ischaemia is 
applied immediately after the onset of reperfusion locally (Andreka et al., 2007). 
 
The lower limbs (Andreka et al., 2007) and the kidney (Kerendi et al., 2005) have 
been demonstrated to confer protection to the heart in ischaemic postconditioning. 
Similar to Pryzyklenk experiments, remote postconditioning of one region of the 
heart conferred protection to another region of the heart undergoing the main 
ischaemic event (Gritsopoulos et al., 2009). 
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1.4.3  Other forms of preconditioning 
 
Rapid right ventricular pacing (Koning et al., 1996), transient hyperthermia 
(Yamashita et al., 2000) and acute myocardial stretch (Ovize et al., 1994) due to 
acute volume overload have also been shown to induce preconditioning.  
 
Gene therapy has been studied to impart long term beneficial effects of 
preconditioning. Specific genes relating to the pharmacological compounds that are 
already known to be protective are used to up regulate certain beneficial enzymes 
including cyclo-oxygenase-2 (Bolli et al., 2007), endothelial nitric oxide synthase and 
inducible nitric oxide synthase (Bolli, 2001). 
 
1.5. Clinical application of conditioning 
 
1.5.1 Clinical application of ischaemic preconditioning and postconditioning 
 
Many clinical studies have been undertaken to exploit the clinical benefit of modifying 
reperfusion injury to decrease infarct size. Most of these early studies used 
ischaemia as a preconditioning or postconditioning stimulus (Von Klemperer, 2010).  
 
Clinical applications of ischaemic preconditioning included intermittent reperfusion 
prior to coronary artery bypass grafting (Yellon et al., 1993) and ischaemic 
preconditioning as an adjunct to cardioplegic arrest (Illes and Swoyer, 1998). These 
studies showed a 75% improvement of ATP preservation in cardiac biopsy and a 
32% improvement of functional outcomes at 12 hours post bypass respectively. In 
particular, the latter did not show any improvement in morbidity or mortality. 
 
Clinical application of ischaemic postconditioning included intermittent reperfusion 
with coronary balloon angioplasty within six hours after the onset of a myocardial 
infarction (Staat et al., 2005). In a similar study, long term follow up was conducted 
(Thibault et al., 2008). These studies showed a 36% reduction in infarct size as 
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measured as the area under the creatine kinase curve and a 7% increase in left 
ventricular ejection fraction at 1 year follow up respectively. A retrospective analysis 
of such trials showed that either three (Darling et al., 2007), or four or more balloon 
inflations were beneficial when applied at reperfusion (Wang et al., 2009a). The most 
recent trial employing ischaemic postconditioning is the upcoming POSTconditioning 
during Coronary Angioplasty in Acute Myocardial Infarction (POST-AMI) trial, the 
results of which are pending since the authors are still collecting data (Tarantini et 
al., 2010). 
 
Due to the success of these clinical trials, researchers have collaborated to form 
guidelines and position papers on the future of conditioning in heart disease. The 
aim is to hopefully enhance the success of other novel bench to bedside translational 
strategies for cardiac protection (Hausenloy et al., 2010a, Ovize et al., 2010).  
 
1.5.2 Clinical evidence of delayed conditioning  
 
Similar to classical preconditioning, many clinical applications of delayed 
preconditioning are restricted to events involving reperfusion injury which can be 
reliably predicted. Pre-infarct angina defined as angina experienced within 24-48 
hours of an acute myocardial infarct has been used as a surrogate for ischaemic 
preconditioning. Thus, patients who experienced pre-infarct angina prior to coronary 
balloon angioplasty had a significantly better regional wall motion as compared to 
their control (Noda et al., 1999). Similar patients who underwent coronary artery 
bypass grafting had reduced creating kinase release (Vahlhaus et al., 2005). 
Unfortunately, no clinical application of delayed postconditioning has been explored. 
 
1.5.3 Clinical application of pharmacological conditioning 
 
The most notable pharmacological preconditioning compound first tested was 
adenosine which was perfused prior to thrombolytic therapy. Adenosine was studied 
in the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trial (Mahaffey et 
al., 1999) and only after subgroup analysis did results show that adenosine was 
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
 
 
27 
 
protective in large infarcts involving the anterior descending coronary artery (Ross et 
al., 2005). Hence AMISTAD II was conducted (Ross et al., 2005) but again, only 
after subgroup analysis did results show that adenosine was protective if infused 
within three hours of onset of a myocardial infarction (Kloner et al., 2006). The 
AndreView Myocardial Imaging for Risk Evaluation (ADMIRE) trial tested the 
synthetic adenosine agonist AMP579 which did not reduce infarct size (Kopecky et 
al., 2003). 
 
Another preconditioning mimetic nicorandil was tested in the Impact of Nicorandil in 
Angina (IONA) study (2002) and most recently the Japanese Coronary Artery 
Disease (JCAD) study (Horinaka et al., 2010). Both studies showed that nicorandil, 
an activator of mitochondrial potassium ATP channels and nitric oxide synthesis, 
significantly decreased major coronary events. However, the relative contribution 
between its two effects has yet to be determined and how does the former effect 
compare to traditional nitric oxide donors and modification of disease, rather than 
just symptomatic treatment (Kojda, 2002).  
 
The peptide hormone, ANP has been used as a postconditioning agent in the Japan-
Working groups of acute myocardial Infarction for the reduction of Necrotic Damage 
(J-WIND) trial. Interestingly, the results of trial showed that nicorandil did not have 
any beneficial effect but ANP did (Kitakaze et al., 2007). It has been proposed by the 
same authors that nicorandil should be administered chronically and ANP should be 
perfused acutely for cardioprotection (Asakura and Kitakaze, 2010). 
 
Cyclosporine has been evaluated as a postconditioning agent in the setting of 
standard coronary balloon angioplasty which has resulted in a decrease in infarct 
size as measured by area under the curve of creatine kinase (Piot et al., 2008). 
Cyclosporine is a known inhibitor of the mitochondrial permeability transition pore 
(Argaud et al., 2005a, Griffiths and Halestrap, 1993) and the pore itself has been 
postulated as the site of convergence for all conditioning stimuli (Hausenloy et al., 
2002).  
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1.5.4 Clinical application of remote preconditioning 
 
The clinical advantage of remote preconditioning is the removal of placing additional 
ischaemia at the site that is already ischaemic. In 2000, Günaydin explored the effect 
of inflation/deflation of blood pressure cuffs prior to coronary artery surgery in 
patients. His results showed that only lactate dehydrogenase levels were 
significantly increased after the removal of the aortic cross clamp as compared to the 
control which implied that preconditioning protected the heart via anaerobic 
glycolysis (Gunaydin et al., 2000). Similar methods of inducing remote 
preconditioning have been used in paediatric patients (Cheung et al., 2006), adults 
undergoing coronary artery bypass grafts (Hausenloy et al., 2007), coronary stenting 
(Hoole et al., 2009) or abdominal aneurysm repairs (Ali et al., 2007). 
 
1.5.5 Clinical application of remote postconditioning 
 
The effect of remote postconditioning has been evaluated in healthy patients and in 
patients with atherosclerotic disease. Only endothelial function was assessed 
showing benefit of preserving flow mediated vasodilation after ischaemia 
(Loukogeorgakis et al., 2006), an effect blocked by the potassium ATP channel 
blocker glibenclamide (Loukogeorgakis et al., 2007). The protective role of remote 
postconditioning during cardio pulmonary resuscitation is still under debate (Mouton 
et al., 2010). 
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1.6 Signalling pathways in conditioning 
 
Since there are a variety of mechanisms involved in conditioning, they have 
conveniently been divided into cell surface receptor activation, signal transduction 
pathways and end effectors.  
1.6.1 Cell surface receptors 
 
Common to preconditioning and postconditioning, are the activation of cell surface 
receptors. These receptors are commonly G-protein coupled receptors which 
activate intracellular signal transduction pathways (Hausenloy and Yellon, 2007) 
(Hausenloy, 2009).  
 
Adenosine was one of the first agents to be discovered as a preconditioning mimetic 
(Liu et al., 1991) and later as a postconditioning mimetic (Kin et al., 2005). Of the 
four subtypes, adenosine receptors A1 and A3 are involved in preconditioning and 
A2B in postconditioning (Jacobson, 2009). The outcome of adenosine’s many 
beneficial effects include coronary artery dilation and negative inotropy (Meldrum et 
al., 1996). 
 
Bradykinin has been described in preconditioning (Wall et al., 1994) and 
postconditioning (Penna et al., 2007). Bradykinin acts via its B2 receptor and signals 
through many mediators such as cyclooxygenase, prostacyclin (Penna et al., 2008), 
cyclic guanine monophosphate and reactive oxygen species (Penna et al., 2007). 
Similar findings have now been extended to human atrial trabeculae studies 
(Lemoine et al., 2010). Bradykinin has been used as a preconditioning mimetic in 
patients undergoing coronary artery bypass grafting resulting in a decreased infarct 
size as measured by the area under the curve of creatine kinase release (Wang et 
al., 2009b) 
 
Statins or hydroxymethylglutaryl-coenzyme A reductase inhibitors are protective in 
preconditioning (Thuc et al., 2010) but not in postconditioning (Kocsis et al., 2008). 
Whilst statins do not bind directly onto receptors, they induce intracellular changes 
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that result in the increased expression of low density lipoprotein cell surface 
receptors. In preconditioning, statins mediates its effects via protein kinase C 
dependent nitric oxide production (Bao et al., 2007), dampening the reactive oxygen 
species burst, hence preventing mitochondrial potassium ATP (mKATP) channel 
opening (Thuc et al., 2010). Their beneficial effects include lowering cholesterol 
levels, releasing nitric oxide (Laufs et al., 1998) and decreasing neutrophil infiltration 
(Lefer et al., 2001). In postconditioning, it is hypothesised that the protocol for 
inducing postconditioning is too brief for statins to have a measurable benefit (Kocsis 
et al., 2008, Iliodromitis et al., 2010). 
 
Ethanol is a known preconditioning (Krenz et al., 2001) and postconditioning mimetic 
(Li et al., 2010). Ethanol cardioprotects via protein kinase C activation but is 
independent of free radicals and mKATP channels (Krenz et al., 2002). However if 
ethanol is also perfused during the index ischaemia, the cardioprotective effect of 
ethanol is lost (Churchill et al., 2008, Krenz et al., 2002). Such findings are in 
agreement with human studies were patients treated with ethanol during 
percutaneous coronary intervention had adverse effects (Niccoli et al., 2008).  
 
TNFα can precondition the heart albeit at low doses (Eddy et al., 1992). TNFα is also 
a necessary requirement for ischaemia preconditioning (Smith et al., 2002) and most 
recently it was confirmed to be involved in ischaemic postconditioning (Lacerda et 
al., 2009). This protective effect of TNFα is thought to be mediated via the activation 
of its cell surface receptors type 2 (Lacerda et al., 2009).  
 
1.6.2  Signal transduction pathways 
 
Several signal transduction pathways have been elucidated for preconditioning but 
only few have been involved in preconditioning and postconditioning. These include 
the survivor activating factor enhancement (SAFE) pathway (see section 2), the 
reperfusion injury salvage kinase (RISK) pathway, reactive oxygen species, protein 
kinase C and the nitric oxide-cGMP-PKG signalling cascade (Figure 5). 
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Figure 5: Schematic diagram representing the signalling pathways of 
ischaemic preconditioning and postconditioning 
The signalling pathways are proposed to merge at the mitochondrial permeability transition pore as 
the common end effector. Abbreviations are provided in the text (Hausenloy and Yellon, 2007).  
 
1.6.2.1  The reperfusion injury salvage kinase (RISK) pathway 
 
Activation of the RISK pathway occurs after ischaemic preconditioning (Tong et al., 
2000) and postconditioning (Tsang et al., 2004). Comprised of phosphatidylinositol-
3-kinase, protein kinase B (PI3K-Akt), and extracellular signal-regulated kinases 
(ERK 1/2), these prosurvival kinases form part of the reperfusion injury salvage 
kinase (RISK) pathway (Hausenloy and Yellon, 2004). Later, other mediators were 
included as downstream mediators, such as protein kinase C (PKC), protein kinase 
G (PKG), p38 mitogen activated protein kinase (p38MAPK), Jun N-terminal kinase 
(MAPK), and glycogen synthase kinase-3β (GSK-3B) (Hausenloy et al., 2010b). 
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During preconditioning, the RISK pathway was found to have a bi-phasic response. 
The first phase occurs immediately after the preconditioning stimulus and prior to the 
index ischemia. The second phase occurs immediately after the index ischaemia 
during the onset of reperfusion (Hausenloy et al., 2005). Both phases were required 
to mediate protection with preconditioning (Hausenloy et al., 2005).  
 
During postconditioning, activation of the RISK pathway is analogous to the second 
phase, as previously described in preconditioning. PI3K-Akt is implicated in 
ischaemic postconditioning as selective inhibition of PI3K by either wortmannin (an 
irreversible inhibitor of PI3K) or LY 294002 (a reversible less potent inhibitor of PI3k 
as compared to wortmannin) abrogated its protective effects (Tsang et al., 2004). 
Similarly, addition of PD-98059, an indirect ERK 1/2 antagonist via the direct 
antagonism of upstream mitogen-activated protein kinase 1/2 (MEK1/2), abrogated 
the protective effects of ischaemic postconditioning (Darling et al., 2005).  
 
1.6.2.2. Reactive oxygen species 
 
Reactive oxygen species (ROS) have concentration dependent effects. At low 
concentration, ROS are protective in preconditioning and postconditioning (Penna et 
al., 2009). At high concentration, ROS are deleterious resulting in membrane lipid 
and DNA oxidation (Zweier et al., 1987). Low ROS concentrations act as signalling 
molecules to activate survival kinases (Samavati et al., 2002), an effect also seen in 
human studies (Loukogeorgakis et al., 2010). Blockade of low ROS concentration 
with oxygen radical scavengers (such as superoxide dismutase) (Tanaka et al., 
1994) or N-2mercaptopropionylglycine (MPG) (Baines et al., 1997) abolish the 
protective role of preconditioning.  
 
1.6.2.3 Protein Kinase C 
 
Protein kinase C (PKC) has been demonstrated to have a protective role in 
ischaemia reperfusion (Yamashita et al., 1994), delayed preconditioning (Baxter et 
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al., 1995), ischaemic preconditioning (Hausenloy et al., 2005) and postconditioning 
(Penna et al., 2006b). Following adenosine A2B receptor stimulation, PKC is 
activated (Philipp et al., 2006) resulting in PKC localising to the mitochondria to 
inhibit mitochondrial permeability transition pore (MPTP) opening (Jaburek et al., 
2006).  
 
Alternatively, PKC can activate the PI3K-Akt pathway downstream and affect the 
ratio of antiapoptotic and proapoptotic proteins to promote cell survival (Hausenloy 
and Yellon, 2004). It remains unknown whether the change in apoptotic protein is as 
a result of direct interaction with PKC or via the PI3K-Akt pathway (Basu and 
Sivaprasad, 2007).  
 
1.6.2.4  The nitric oxide-cGMP-PKG-signalling cascade 
 
This pathway has been implicated in preconditioning (Lochner et al., 1998) and 
postconditioning (Penna et al., 2006a). Nitric oxide (NO) can activate guanylate 
cylase to result in the conversion of guanosine triphosphate to cyclic guanosine 
monophosphate (cGMP). In turn, low concentrations of cGMP inhibit 
phosphodiesterase while  high concentrations of cGMP activates PKG (Schulz et al., 
2004). PKG mediates the protective effects of this pathway via regulation of calcium 
homeostasis (Piper et al., 2004), mediate MPTP opening (Costa et al., 2005) and 
prevent apoptosis via anti-apoptotic B-cell lymphoma 2 (Bcl-2) (Razavi et al., 2005). 
 
1.6.3  End effectors 
 
Mitochondria provide energy for the cell but also play a critical role in determining the 
cells fate (Zamzami et al., 1996). In fact, the signalling pathways converge on the 
mitochondria to initiate either prosurvival or apoptotic pathways during ischaemia 
reperfusion injury (Baines, 2009). Research has primarily focused on the opening of 
mitochondrial potassium ATP (mKATP) channel and closure of the MPTP as 
prosurvival mechanisms during reperfusion (Mykytenko et al., 2008, Yang et al., 
2004). 
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1.6.3.1  Mitochondrial potassium ATP channel 
 
Despite disagreement on the existence of the putative mKATP channel (Halestrap et 
al., 2007), many researchers have continued to explore the protective effect of the 
mKATP channel (Costa and Garlid, 2009). Opening of the mKATP channel was 
found to be beneficial in ischaemia reperfusion (Garlid et al., 1997), ischaemic 
preconditioning (Garlid et al., 1996) and postconditioning (Krolikowski et al., 2005). 
The physiological role of the mKATP channel is proposed to help stabilise the 
mitochondria during increased inotropy demand by the heart. Hence, with increase 
demand for ATP, opening of the mKATP channel results in stabilisation of the inner 
mitochondrial membrane to prevent disruption of the voltage dependent anion 
channel and hence allow efficient energy transfer (Costa and Garlid, 2009).  
 
During reperfusion, it is proposed that numerous signals converge to open the 
mKATP channel via either PKG or protein kinase C epsilon (PKCε) which then 
phosphorylate receptors 1 and 2 on the outer mitochondrial membrane respectively. 
These receptors then phosphorylate PKCε on the inner membrane to open the 
mKATP channel, resulting in potassium influx and ROS production via complex I to 
alkalinise the inner membrane (Costa and Garlid, 2009, Costa et al., 2006). In 
addition to mKATP opening, ROS signalling results in the inhibition of MPTP opening 
(Krolikowski et al., 2005, Costa and Garlid, 2009). Hence, many are now considering 
the mKATP to have a signalling role rather than being an end effector (Pain et al., 
2000). 
 
1.6.3.2. Mitochondrial permeability transition pore (MPTP) 
 
MPTP closure is important in ischaemic preconditioning (Hausenloy et al., 2002) and 
postconditioning (Argaud et al., 2005b). MPTP closure prevents dissipation of the 
proton electrochemical gradient necessary for aerobic energy generation and 
prevents influx of small proteins and water inside the mitochondria. Hence, 
mitochondrial swelling is prevented, with no rupture and release of pro-apoptotic 
proteins into the cytosol (Baines, 2009) and a concomitant reduction in the 
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availability of ATP (Halestrap et al., 2004). Therefore many signalling pathways 
converge on the MPTP including PKG, PKC, mKATP, Akt, Erk 1/2 and GSK-3β 
(Hausenloy et al., 2009).  
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2 The Survivor Activating Factor Enhancement (SAFE) 
pathway 
 
The Survivor Activating Factor Enhancement (SAFE) pathway has recently been 
described (Lecour, 2009b) and is activated during ischaemic preconditioning (Lecour 
et al., 2005b). Evidence has demonstrated that the SAFE pathway is an alternative 
protective pathway as compared to the RISK pathway. However, cross-talk or 
additive effects between the two pathways have not been clarified (Lecour, 2009a, 
Lecour, 2009b). 
 
The SAFE pathway is comprised of TNFα, its cell surface receptors and its signal 
transduction pathway, the Janus kinase/Signal transducer and activator of 
transcription 3 (JAK/STAT-3).  
 
2.1  TNFα and the SAFE pathway 
 
TNFα and its similar isoform TNFβ, have many functions including their regulation of 
inflammation, cell survival, growth, differentiation and apoptosis (Meldrum, 1998). 
TNFα is not only produced by immune cells but also by nucleated cells, including 
myocardial cells (Mann, 2003).  
2.1.1. TNFα receptors 
 
TNFα has two cell surface receptors, namely TNFα receptor 1 (TNFR1) and 2 
(TNFR2) otherwise known as CD120a/p55/60 or CD120b/p75/80 respectively. 
(Krown et al., 1995, Torre-Amione et al., 1995). In general, TNFR1 mediates 
proinflammatory and programmed cell death pathways while TNFR2 mediates tissue 
repair and angiogenesis (Kleinbongard et al., 2010). In fact, it was recently described 
that TNFα binds to  TNFR2 to mediate its protective effect via the SAFE pathway 
(Lacerda et al., 2009).  
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Interestingly, a TNFα binding protein on the mitochondria has been demonstrated, 
suggesting a direct link of TNFα to the mitochondria, independent of cell surface 
receptor activation (Ledgerwood et al., 1998, Busquets et al., 2003, Lacerda et al., 
2010). 
 
2.1.2. TNFα and ischaemia reperfusion 
 
The role of TNFα in ischaemia reperfusion is controversial in humans. Although it is 
elevated after an acute myocardial infarction, interventions aimed at reducing TNFα 
by anti-TNFα antibodies resulted in increasing mortality (Mann, 2002). Conversely, 
animal models have shown beneficial effects of TNFα blockade (Gurevitch et al., 
1997, Belosjorow et al., 2003) or genetic lack thereof (Maekawa et al., 2002). Hence 
there is a disparity in clinical evidence versus basic research.  
 
Such disparities can be explained by the differential effects of concentration, timing, 
duration of treatment, or recruitment of different receptors (Schulz and Heusch, 
2009). High concentrations of TNFα can be deleterious as opposed to low 
concentrations (Deuchar et al., 2007, Sack, 2002, Lecour et al., 2005b, Lecour et al., 
2002). With increasing duration of ischaemia, TNFα is released initially from resident 
mast cells (Gilles et al., 2003) and macrophages but later from the myocardium 
(Dorge et al., 2002). 
 
2.1.3 TNFα and conditioning 
 
The role of TNFα in humans has been implicated in remote ischaemic 
preconditioning (Zhou et al., 2010) and ischaemic postconditioning (Lin et al., 2010). 
Remote ischaemic preconditioning was conducted in paediatric patients undergoing 
open heart surgery resulting in a significant post-operative decline of TNFα. Post-
operative morbidity and mortality were not affected. However, it was postulated that 
sicker patients are likely to benefit from the reduced post-operative ischaemia 
reperfusion injury and systemic inflammatory response syndrome (Zhou et al., 2010). 
Ischaemic postconditioning after an acute myocardial infarction resulted in 
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decreased TNFα levels and it was proposed that TNFα concentration and wall 
motion score index were valuable prognostic markers (Lin et al., 2010). 
 
TNFα in animal models have been demonstrated to acts as a preconditioning 
(Lecour et al., 2005b) and postconditioning (Lacerda et al., 2009) mimetic. Similarly, 
blockade of TNFα with antibodies (Yamashita et al., 2000) or use of TNFα knockout 
mice during preconditioning (Smith et al., 2002) can increase infarct size. Similarly, 
TNFα knockout mice cannot be postconditioned (Lacerda et al., 2009). Interestingly, 
exogenous TNFα can only protect the heart if there is a washout period prior to the 
main ischaemic event suggesting that TNFα induced protection is time dependent 
(Lecour, 2009a, Lecour et al., 2002). Furthermore low concentrations of TNFα can 
preconditioning the heart but higher concentrations of TNFα are deleterious, 
demonstrating that TNFα’s cardioprotective effect is also concentration dependent 
(Lecour et al., 2002). 
 
2.2 JAK/STAT-3 and the SAFE pathway 
 
Activated during episodes of stress, the JAK/STAT-3 pathway transmits signals from 
the cell surface to the nucleus to modulate gene expression (Bolli et al., 2003). 
Various ligands can bind to their cell surface receptors including interleukin 6, growth 
factors and TNFα. Thereafter, the associated cytosolic JAK homodimerises and 
phosphorylates to transphosphorylate and activate STAT-3  (Meyer et al., 2003). 
Activated STAT-3 can then form homodimers or heterodimers with other members of 
the STAT family. These include STAT-1 to STAT-6, however only STAT-3 will be 
considered in this thesis because thus far only STAT-3 has been proposed to be 
involved in the SAFE pathway (Lecour, 2009a). However, it does not preclude the 
importance of other STAT isoforms such as STAT-1, the benefits of which are 
discussed elsewhere (Boengler et al., 2008b). Dimerised STAT-3 translocates to the 
nucleus to bind to interferon gamma activated sequence (GAS) motifs to promote 
end target genes (Levy and Darnell, 2002) (Figure 6). In addition, STAT-3 has the 
potential to regulate mitochondrial function and thus is proposed to regulate MPTP 
opening (Boengler et al., 2010). 
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Figure 6: Schematic diagram of JAK/STAT-3 pathway 
Please refer to text for details. Modified from Lecour et al. (Lecour, 2009a). 
 
Although gene expression intuitively may require hours to initiate protection, the 
JAK/STAT-3 pathway can initiate protection with minutes of ischaemic 
preconditioning (Lecour et al., 2005b) and postconditioning stimuli (Boengler et al., 
2008a). Such immediate protection has been postulated to be the result of cross talk 
with other signalling cascades (Hausenloy and Yellon, 2007) or direct effects on end 
effectors such as the mitochondria (Wegrzyn et al., 2009, Lecour, 2009a, Lacerda et 
al., 2010). 
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Current controversies regarding the paradigm of JAK/STAT-3 signalling include the 
following (Sehgal, 2008); First, nonphosphorylated STAT-3 dimers exist in the 
cytosol. Second, nonphosphorylated STAT-3 shuttles constitutively between cytosol 
and nucleus. Third, nonphosphorylated STAT-3 can be transcriptionally active but 
activate a different set of genes. Fourth, cytosolic to nuclear transport can take place 
via endocytic trafficking. Fifth, not all STAT-3 mediate effects are via the nucleus but 
includes the cytoplasm, of which its association with mitochondria is one of many 
examples (Wegrzyn et al., 2009). The effects of such shifts in the current paradigm 
of JAK/STAT-3 signalling have yet to be determined. 
 
2.2.1  JAK/STAT and ischaemia reperfusion 
 
The JAK/STAT pathway is activated following ischaemia reperfusion and 
pharmacological blockade of JAK by AG490 results in inhibition of STAT-3 
phosphorylation and increased apoptosis (Negoro et al., 2001, Negoro et al., 2000). 
Cardiac specific over expression of STAT-3 decreased infarct size (Oshima et al., 
2005)  and cardiac specific deletion of STAT-3 increased infarct size (Smith et al., 
2004). Both studies emphasise the protective nature of STAT-3 against ischaemia 
reperfusion. In contrast, some studies have found that addition of AG490 protected 
the heart (Hwang et al., 2005, Mascareno et al., 2001).  
2.2.2  JAK/STAT and conditioning 
 
During ischaemic preconditioning both JAK/STAT and PI3K-Akt (RISK) pathways are 
required to confer protection (Suleman et al., 2008, Hausenloy et al., 2009). 
However, if TNFα is used as a preconditioning mimetic, only the JAK/STAT pathway 
is activated and not the RISK pathway because Erk1/2 inhibition by PD98059 
(Lecour et al., 2005b) and PI3K-Akt inhibition by wortmannin (Suleman et al., 2008) 
could not abrogate TNFα preconditioning. Similar results were achieved with TNFα 
postconditioning (Lacerda et al., 2009).  
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STAT-3 knock out (KO) mice cannot be preconditioned (Smith et al., 2004). 
Likewise, pharmacological blockade of the JAK/STAT pathway by AG490 in wild 
type mice prevents any protective effects of the SAFE pathway during 
preconditioning (Suleman et al., 2008). At the time I started my MSc degree, the role 
of STAT-3 via postconditioning was unknown. 
 
Therefore, the use of TNFα to activate the JAK/STAT pathway resulting in protective 
effects against reperfusion injury, has been termed the SAFE pathway and is an 
independent signalling pathway to the already described RISK pathway (Lecour, 
2009a) (Figure 7). 
 
 
 
Figure 7: Schematic diagram of the SAFE and RISK pathway 
See text for abbreviations (Lacerda et al., 2009).  
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2.3 Downstream effectors of the SAFE pathway 
 
Known downstream targets include genes activated by STAT-3. These include 
inducible nitric oxide synthase and cyclooxygenase 2 although these genes were 
elucidate in a mouse model undergoing delayed preconditioning by interleukin 6 
signalling (Dawn et al., 2004). Similarly, antiapoptotic Bcl-2 and B-cell lymphoma-
extra large (Bcl-Xl) are activated by STAT-3 via interleukin 6 signalling in myeloma 
cells (Schwarze and Hawley, 1995) and pharmacological postconditioning with 
opioids (You et al., 2011). 
 
Other known end effectors of the SAFE pathway include the mKATP channel 
(Lecour et al., 2002), NFκ-B (Somers, 2005) and inhibition of proapoptotic BAD 
(Lecour et al., 2005b). In contrast, neither Akt, Erk, p38MAPK nor GSK3β are 
involved in the SAFE pathway (Lacerda et al., 2009, Lecour et al., 2005b, Tanno et 
al., 2003).  
 
Recent research has focused on the MPTP as the final downstream effector for the 
SAFE pathway. It was recently discovered that STAT-3 can regulate mitochondrial 
metabolic function (Gough et al., 2009, Boengler et al., 2010) and proposed to have 
a direct interaction with complex I/II on the inner mitochondrial membrane (Wegrzyn 
et al., 2009). However, other researchers disagree and state that STAT-3 mediates 
its effects via nuclear transcription, or at the very least, in close association with 
mitochondria but indirectly (Phillips et al., 2010). Interestingly STAT-3, specifically its 
serine phosphorylation motif, has been implicated as a regulator in mitochondrial 
respiration, independent of its nuclear transcription effects (Wegrzyn et al., 2009). 
Finally, the MPTP has recently been proposed to be common end protector between 
the RISK and SAFE pathways (Hausenloy et al., 2010b).  
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3 The FOXO pathway and conditioning 
 
Forkhead box O (FoxO) has many diverse functions including apoptosis and 
mediating the response to oxidative stress (Maiese et al., 2008). FoxO has many 
subtypes including FoxO1, FoxO3, FoxO4 and FoxO6. Each subtype has a 
predilection for certain tissues such as adipose, liver, muscle and brain, respectively. 
Regarding muscle, FoxO4 is more specific to skeletal muscle and FoxO3 is 
expressed more than FoxO1 in cardiac muscle (Furuyama et al., 2000). 
3.1  Apoptotic function of FoxO 
 
One of the most important FoxO mediated pathways is apoptosis. Depending on the 
stimulus and hence the relevant signalling pathway, FoxO can either have an 
antiapoptotic or proapoptotic role. 
 
3.1.1 Antiapoptotic role of FoxO 
 
FoxO antiapoptotic pathways can broadly be divided into Akt or non-Akt dependent 
pathways. In response to ischaemia, Akt can phosphorylate and hence inactivate 
either the cytoplasmic or nuclear pool of FoxO3a.  As a result, cytoplasmic FoxO3a 
will be bound to the 14-3-3 protein (Biggs et al., 1999) and nuclear FoxO3a will be 
exported out of the nucleus by the 14-3-3- protein (Brunet et al., 2002). Hence, 
nuclear FoxO3a is unable to mediate its transcription of genes to induce apoptosis 
such as Bcl-2-interacting mediator of cell death (Bim) (Huang and Tindall, 2007, 
Dijkers et al., 2000) 
 
Non-Akt pathways include serum and glucocorticoid inducible protein kinase (Sgk) 
and S-phase kinase-associated protein-2 (Skp2). Similar to Akt, Sgk can 
phosphorylate FoxO3a to bind it to the 14-3-3-protein and hence prevent apoptosis 
(Leong et al., 2003, Brunet et al., 2001). Within the nucleus, Skp2 can degrade 
FoxO1 via an ubiquitin-dependant pathway (Huang et al., 2005). An inverse 
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relationship exists between Skp2 and FoxO3a levels, although the mechanism of 
their interaction has yet be to described (Lu et al., 2009). 
 
3.1.2 Proapoptotic role of FoxO 
 
Proapoptotic pathways allow dephosphorylated FoxO to accumulate in the nucleus 
and hence activate proapoptotic pathways. The pathways which enable apoptosis 
can be divided into the extrinsic and intrinsic pathways. 
 
The extrinsic pathway can be modulated by dephosphorylated FoxO3a following the 
genetic expression of TNF-related apoptosis-inducing ligand (TRAIL) (Modur et al., 
2002, Obexer et al., 2007) and Fas/CD95 (Brunet et al., 1999, Barthelemy et al., 
2004). These cell surface receptors can then activate caspases to induce apoptosis. 
 
The intrinsic pathway can be modulated by dephosporylated FoxO3a by up 
regulation of genes encoding for Bim and Noxa (equivalent to phorbol-12-myristate-
13-acetate-induced protein). These two proteins from part of a classification system 
that recognises the number of conservatively shared Bcl-2 homology (BH) domains, 
Hence Bim and Noxa are similar to BAD, all of which are BH3 only proteins. BH3 
proteins can bind BH1234 proteins hence allowing BH123 proteins to induce outer 
membrane permeabilisation with subsequent cytochrome C release and caspase 
activation (Obexer et al., 2007).  
 
3.2 FoxO response to oxidative stress  
 
In response to oxidative stress by hydrogen peroxide for example, FoxO3a is 
deacetylated by silent information regulator 1 (Sirt1) and together form a complex 
(Brunet et al., 2004). The Sirt1/FoxO3a complex will allow FoxO3a to bind promoters 
of genes that increase manganese superoxide dismutase (MnSOD) (Kops et al., 
2002)  and catalase (Nemoto and Finkel, 2002). These enzymes will subsequently 
combat the increase in ROS caused by the oxidative stress. In addition, the 
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Sirt1/FoxO3a complex will prevent FoxO3a from increasing BIM expression and 
hence, prevent apoptosis during oxidative stress (Motta et al., 2004). Recently it was 
demonstrated that in addition to FoxO3a, FoxO1 also localised to the nucleus in 
response to oxidative stress, resulting in an increase in MnSOD and catalase 
amongst others (Sengupta et al., 2010).  
 
The response to starvation or ischaemia-reperfusion in cardiomyocytes has resulted 
in dephosphorylation of FoxO1 and FoxO3 which up regulates genes necessary for 
autophagy (Sengupta et al., 2009).  
 
3.3 FoxO and ischaemia reperfusion 
   
Following ischaemia reperfusion, myocardial overexpression of H11 kinase (a 
eukaryotic homologue of the viral protein kinase expressed after herpes simplex viral 
infection) resulted in cardioprotection, in part mediated by FoxO1a (Depre et al., 
2006). Similarly, in the brain subjected to ischaemia reperfusion, Akt phosphorylation 
prevented FoxO3a from inducing Fas and BIM expression (Shioda et al., 2007).  
 
Phosphorylated cytoplasmic FoxO3 was reduced and hence active in ischaemia 
reperfusion, resulting in nuclear FoxO3 to induce autophagy in cardiomyocytes 
(Sengupta et al., 2009). FoxO3 is also deacetlyated by Sirt1 and Sirt1 is increased in 
ischaemia reperfusion. Although Sirt1 is located in the cytosol and nucleus at rest 
(Tanno et al., 2007), following ischaemia and reperfusion Sirt1 locates predominately 
to the nucleus (Brunet et al., 2004). FoxO3 then activates primarily GADD45 (a DNA 
repair target gene) and not BIM expression (Brunet et al., 2004).  
 
Recently it was described that FoxO1 could translocate to the nucleus and increase 
expression of manganese superoxide dismutase in response to Sirt1 induced 
cardioprotection following ischaemia reperfusion (Hsu et al., 2010). 
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3.4 FoxO and conditioning 
 
Very little is known about the role of FoxO in preconditioning and none is known in 
postconditioning. Bromelin, a proteolytic enzyme extracted from pineapple, is a 
preconditioning mimetic which reduced apoptosis following myocardial ischaemia 
reperfusion via Akt mediated phosphorylation of FoxO3a (Juhasz et al., 2008). 
Another study utilised protein H11 kinase (H11k) cardiac specific over expressing 
mice to demonstrate the cardioprotective role of H11k. H11k binded to Akt and 5’ 
AMP-activated protein kinase (AMPK) to inhibit FoxO1, GSK3β, BAD amongst 
others (Depre et al., 2006). Similar effects were achieved in rat brain where 
ischaemic preconditioning resulted in activation and phosphorylation of Akt and 
hence sustained phosphorylation of FoxO1, FoxO3 and FoxO4 to prevent apoptosis 
(Zhan et al., 2010). The role of FoxO as a potential downstream effector of the SAFE 
pathway has yet to be explored. 
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4 Sphingosine 1 phosphate and conditioning 
 
Sphingolipids form part of all eukaryotic cell membranes, mechanically stabilising the 
membrane and chemically forming part of the hydrophobic lipid bi-layer (Takabe et 
al., 2008). One of the sphingolipids, sphingosine, is converted by sphingosine kinase 
(SpK) to form sphingosine 1 phosphate (S1P) (Takabe et al., 2008). In addition to its 
membrane location, 60% of plasma S1P concentrations are found in high density 
lipoprotein (HDL), where S1P can mediate HDL’s protective effects (Keul et al., 
2007). 
 
S1P has many functions including cytoskeletal migration, vasculogenesis, cell 
growth, lymphoid tracking, intracellular calcium mobilisation and chemokine 
attractant (Cyster, 2005, Karliner, 2009). In particular, S1P has a regulatory role in 
cell survival (Olivera and Spiegel, 1993) and apoptosis (Cuvillier et al., 1996). The 
pleiotropic nature of S1P can be attributed to its intracellular and extracellular effects. 
Intracellular S1P production via sphingosine kinase enables S1P to act as a second 
messenger to increase DNA synthesis and mobilise calcium from internal stores 
(Payne et al., 2002). Importantly, via extracellular secretion, S1P can bind to its cell 
surface receptors (Spiegel and Milstien, 2003).  
 
S1P has 5 receptors named in numerical order. S1P receptors 1 to 3 (S1P1, S1P2 
S1P3) are found in cardiomyocytes with S1P1 the most dominant. S1P4 and S1P5  
are limited to immune and nervous systems (Means and Brown, 2009). In contrast, 
cardiac fibroblasts express more S1P3 than S1P1 and S1P2 receptors (Landeen et 
al., 2008) and since they are the most abundant cell type in the heart, the role of S1P 
via the activation of it receptors is non negligible (Kacimi et al., 2007). In addition, 
cardiac fibroblasts can functionally organise the cardiomyocytes, enabling the 
cardiomyocytes to respond to stimuli (Means and Brown, 2009). 
 
Following extracellular secretion, S1P can bind to and activate G-protein coupled 
S1P receptors. Thereafter, activation of either ERK or PI3K-Akt will lead to cell 
proliferation or cell survival respectively (Radeff-Huang et al., 2004). S1P has also 
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been shown to activate Akt and inactivate GSK-3β during cardiomyocyte hypoxia 
(Zhang et al., 2007).  
 
Intracellular effects of S1P are mainly confined to its production from sphingosine by 
sphingosine kinase and its breakdown to ceramide (Melendez, 2008, Taha et al., 
2006) (Figure 8). S1P is known to be pro-growth and anti-apoptotic, but sphingosine 
and ceramide have mainly anti-proliferative and pro-apoptotic effects (Cuvillier et al., 
1996). Therefore, the concept of a ‘sphingolipid rheostat’ was proposed, indicating 
the dynamic role between the three compounds which ultimately determines the cells 
fate (Spiegel and Milstien, 2002).  
 
Importantly, the two isoforms of SpK, namely SpK1 and SpK2 strongly influence the 
sphingolipid rheostat. SpK1 converts sphingosine to S1P and decreases ceramide 
levels, thereby promoting cell survival. Conversely, SpK2 increases ceramide levels 
thereby promoting cell death (Maceyka et al., 2005).  
 
Interestingly, TNFα can promote cell survival by activating SpK1 directly, 
independent of S1P cell surface receptors but rather via the TNF receptor-
associated factor 2 (TRAF2) (Xia et al., 2002). In addition, TNFα, by binding to 
TNFR2 and then via TRAF2, can induce nuclear factor kappa B (NF-κB) to prevent 
apoptosis (Rothe et al., 1995, Wang et al., 1998).  
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Figure 8: Sphingolipid metabolic pathway 
Sphingomyelin is hydrolysed by sphingomyelinase to ceramide. Ceramide is metabolised by 
ceramidase to generate sphingosine, or ceramide can be phorphorylated by ceramide kinase to 
generate ceramide-1-phosphate. Alternatively, sphingomyelin synthase can convert ceramide back to 
sphingomyelin. Ceramide-1-phosphate can be dephosphorylated by lipid phosphate phosphatase 
(LPP) back to ceramide. Sphigosine-1-phosphate can be dephosphorylated to produce sphingosine 
(by S1P phosphatases or LPP) or it can be irreversibly cleaved by S1P lyase to hexadecanal and 
phosphoethanolamine (Melendez, 2008). 
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4.1 S1P and ischaemia/reperfusion 
 
Following the protective effects of S1P in hypoxia (Karliner et al., 2001), its role in 
myocardial ischaemia/reperfusion was described (Jin et al., 2002, Lecour et al., 
2002, Egom et al., 2010). Akt (Hofmann et al., 2009) and nitric oxide have thus far 
been implicated to mediate S1P’s protective effects (Theilmeier et al., 2006). 
Interestingly, PKCε is also involved in S1P signalling but not via exogenous S1P 
administration. Rather, endogenous S1P production stimulates PKCε via addition of 
a ganglioside which in turn activates SpK1 (Jin et al., 2002). 
 
4.2 S1P and conditioning 
 
S1P has been shown to be both a preconditioning (Jin et al., 2002, Lecour et al., 
2002, Vessey et al., 2009b) and a postconditioning mimetic (Hofmann et al., 2009, 
Vessey et al., 2009b, Somers, 2009). Furthermore, its interaction with one of its 
metabolites, sphingosine has been explored. Whilst S1P may mediate its effects 
through G protein coupled receptors, sphingosine mediates protection through 
protein kinase G or C. However, both S1P and sphingosine pathways unite through 
the activation of Akt in either preconditioning or postconditioning (Vessey et al., 
2008b). 
 
Similar research has focused on endogenous S1P production via SpK1 during 
ischaemia reperfusion. Knockout SpK1 mice failed to be protected by ischaemic 
preconditioning (Jin et al., 2007) and postconditioning (Jin et al., 2008, Hofmann et 
al., 2009).  
 
Recently it was proposed that S1P and adenosine could independently protect the 
heart because VPC 23019, a S1P1and3 antagonist and 8-SPT, a adenosine receptor 
antagonist, could abrogate their respective protective conditioning effect. However, if 
the ischaemic repetitive cycles in preconditioning and postconditioning were 
increased from two to three, and from four to five cycles respectively, VPC 23019 
and 8-SPT could not individually inhibit the protective effect of ischaemic 
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conditioning but together they could. Hence the authors suggest that in as much as 
one agent could be cardioprotective, if the strength of ischaemic conditioning were 
increased, it was no longer dependent on a single pathway (Vessey et al., 2009b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
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Chapter Two: Aim, Hypothesis and Objectives 
 
Pharmacological conditioning and ischaemic conditioning are powerful tools to 
reduce damage following ischaemia reperfusion but the mechanisms still remains 
unclear. JAK/STAT, as part of the SAFE pathway has recently been delineated as a 
critical and important pathway in ischaemic preconditioning but whether activation of 
STAT-3 is required for the protection of pharmacological preconditioning with S1P 
and ischaemic postconditioning is unknown. 
 
2.1 Aim 
 
The aim of this thesis was to explore the role of STAT-3 in the cardioprotective effect 
of preconditioning and postconditioning.  
 
2.2  Hypothesis 
 
We hypothesised that S1P preconditioning and ischaemic postconditioning protect 
via activation of STAT-3.  
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2.3  Objectives 
To asses this hypothesis, the following objectives were pursued: 
 
1. To investigate the role of STAT-3 in S1P preconditioning, we used a cell 
culture (fibroblast) model and an isolated rat heart model subjected to an 
ischaemic insult, in the presence of a pharmacological inhibitor of the STAT-3 
pathway (AG490). Cell survival, infarct size and western blot analysis were 
used as an endpoint. 
 
2. To investigate the role of STAT-3 in ischaemic postconditioning, we used an 
isolated rat heart model subjected to either a global or regional ischaemic 
insult in the presence of a pharmacological inhibitor of the STAT-3 pathway 
(AG490). Infarct size and western blot analysis were used as an endpoint.  
 
 
Figure 9: Schematic diagram of hypothesis 
S1P preconditioning and ischaemic postconditioning activate STAT-3 as a result of ischaemia 
reperfusion to result in cardioprotection. 
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Chapter Three: Material and methods 
 
3.1 Isolated fibroblasts 
 
Mouse L cell fibroblasts were initially grown from frozen vials stored in 1% dimethyl 
sulfoxide (DMSO) and seeded into flasks containing a medium of dimethyl sulfoxide 
(DMSO) (Highveld Biologicals, RSA) with 10% fetal calf serum (FCS) (Highveld 
Biologicals, South Africa) and 2 % L-glutamine (Sigma, Germany). The flasks were 
placed in a 5% CO2 incubator maintained at 37°C and 95% humidity. After 6 hours, 
the medium was replaced with DMEM to remove the cytotoxic DMSO. Thereafter, 
the medium was replaced every 48 hours until 80-90% confluence (72 hours) was 
reached and then the cells were split. 
 
In order to split the cells, the cells were trypsinised and hence incubated for 3 
minutes with 0.25% Trypsin (w/v) and 0.2% ethylenediaminetetraacetic (EDTA) (w/v) 
(Sigma, Germany). After 3 minutes, the Tryspin/EDTA solution was neutralised with 
double the volume DMEM and 10% FCS. A 15µl sample solution was counted on the 
Neubauer hemocytometer and the remaining solution centrifuged for 5 minutes at 
1000 rpm at 4°C, and the cell pellet resuspended in DMEM. The final concentration 
would be approximately 1 million cells per ml of solution. 
 
Therefore, to maintain cell lines, 2 million cells or 2ml of cells in DMEM were seeded 
into 75cm3 flasks. For experiments, 0.5 million cells or 0.5ml of cells in DMEM were 
seeded into 25cm3 flasks and allowed to reach 80-90% confluence (48 hours). 
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3.1.1. Simulated ischaemia 
 
To replicate the metabolic changes associated with ischaemia, a modified Esumi or 
simulated ischaemia buffer was used (Esumi et al., 1991) and the cells were 
incubated in a hypoxic environment. The simulated ischaemia buffer consisted of 
137 mM NaCl, 12 mM KCl, 0.5 mM MgCl, 0.9 mM CaCl2, 20 mM Hepes, 20 mM 2-
Deoxy-d-Glucose (2-DG) adjusted to a pH of 6.4. 2-DG is added because it 
irreversibly inhibits glycolysis and hence further mimics ischaemia. Furthermore, the 
cells were exposed to a hypoxic environment in a sealed incubation chamber set at 
37°C and a gas controller (Gentronics, South Africa) was used to set oxygen levels 
at 1.5% ± 1.0% and carbon dioxide levels at 5.0% ± 2.5%.  
 
3.1.2. Preconditioning protocol for isolated fibroblasts 
 
A normoxic group consisted of cells not exposed to simulated ischaemia but 
exposed to the same amount of washes with phosphate buffered saline (PBS). The 
simulated ischaemia group was washed twice with PBS prior to incubation with 
simulated ischaemia buffer and the hypoxic environment for 8.5 hours. The S1P 
preconditioning group was incubated with S1P (10 nmol/L) in DMEM for 30 minutes, 
washed with PBS twice, incubated with drug free DMEM for 30 minutes before being 
washed again with PBS and subjected to simulated ischaemia. The S1P and AG490 
preconditioning group was incubated with S1P (10 nmol/L) and AG490 (100 nmol/L) 
in DMEM for 30 minutes, washed with PBS twice, incubated with drug free DMEM 
for 30 minutes before being washed again with PBS and subjected to simulated 
ischaemia (Figure 10). At the end of the simulated ischaemia, cell viability was 
assessed. 
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1. Normoxic control 
 
 
2. Simulated ischaemia control 
 
 
3. S1P preconditioning 
 
 
4. S1P+AG490 preconditioning 
 
 
 
 
 
SI = Simulated ischaemia   AG490    cell viability 
 
Figure 10: Schematic diagram of isolated fibroblasts undergoing 
preconditioning 
See text for details. 
 
3.1.3 Cell viability 
 
The trypan blue exclusion technique for cell viability was used. The technique 
required that after the simulated ischaemia, cells were washed twice and incubated 
with 0.25% trypsin at 37°C for 3 minutes as previously described (Suleman et al., 
2008). Trypsin was neutralised with double volume DMEM and centrifuged for 5 
minutes at 1000rpm at 4°C. After discarding the supernatant and resuspending the 
pellet in 2ml of DMEM, 15µl of cell solution was stained with an equal volume of 
0.4% Trypan blue (Sigma, Germany). The combination was analysed under a light 
microscope using a Neubauer hemocytometer. 
 
Trypan blue will stain dead cells in blue due to their damaged membranes whilst 
alive cells would remain clear. Hence, the ratio of blue stained dead cells to 
unstained alive cells was calculated and expressed as a percentage.  
S1P 
30 min 30 min 8.5 hours 
SI 
 
SI 
 
S1P+AG SI 
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3.2  Animals 
 
All experiments were conducted on Male Wistar (200-350g) rats as housed by the 
University of Cape Town Animal Unit. All protocols were carried out in compliance 
with the Guide for the Care and Use of Laboratory Animals published by the U.S. 
National Institutes for Health (NIH Publication No. 85 (23), revised 1996).  The 
experimental protocol was approved by the Faculty of Health Sciences Animal Ethics 
Committee, University of Cape Town (06/031).   
 
3.3  Isolated rat heart model 
 
Rats were anaesthetised with sodium pentobarbital (50 mg/kg i.p.) and heparinised 
(500 IU) i.p. Hearts were rapidly excised, cannulated via the aorta and perfused 
retrogradely using the Langendorff isolated rat heart model. The system perfused the 
hearts at a constant pressure of 100cm H20 at 37°C with Krebs-Henseleit buffer 
equilibrated with oxygen/carbon dioxide ratio of 95:5%. The final composition of the 
buffer was as follows (in mM): 118.5 NaCl, 25 NaHCO3, 4.75 KCL, 1.18 
MgSO4.7H2O, 1.2 KH2PO4 1.36 CaCl2.2H20 and 11.1 Glucose, pH of 7.4. 
 
A water filled balloon was inserted into the left ventricle via the left atrium which was 
connected to a pressure transducer and data were recorded on a Powerlab Labchart 
(ADI Instruments, Australia). Temperature was measured with a fine thermocouple 
wire (Physitemp, NJ, USA), inserted into the left atrium and monitored with a Digitron 
2600T temperature sensor (Torquay, UK). The left ventricular end diastolic pressure 
was adjusted between 4 and 12 mmHg. Various cardiac parameters were measured 
throughout the experiments, including heart rate, coronary flow rate and left 
ventricular developed pressure (LVDP). The latter is calculated as the difference 
between left ventricular end systolic pressure and left ventricular end diastolic 
pressure. Rate pressure product (RPP) was calculated as LVDP multiplied by heart 
rate and expressed as a percentage of baseline. 
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3.3.1  Exclusion criteria 
 
Rat hearts which did comply with the following criteria were excluded: 
1) Left ventricular pressure greater than 80 mmHg. 
2) Coronary flow rate at a minimum of 8 ml per minute and a maximum of 16ml 
per minute. 
3) Heart rate at a minimum of 240 beats per minute and a maximum of 400 
beats per minute. 
A total of 22 rats were hence excluded from the study. 
 
3.3.2  Isolated rat heart perfusion protocols 
 
As previously described, isolated rat heart perfusions were divided into 
preconditioning and postconditioning stimuli. Furthermore, whilst preconditioning was 
conducted only under regional ischaemia, postconditioning was divided into global 
and regional ischaemia. 
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3.3.2.1  Preconditioning protocol in isolated rat hearts  
 
In the ischaemic control group, isolated rat hearts were subjected to 30 minutes of 
stabilisation, 30 minutes of regional ischaemia followed by 120 minutes of 
reperfusion. Regional ischaemia was induced by ligating the anterior descending 
coronary artery with a 3/0 silk suture snare.  
 
In the ischaemic preconditioning group, 7 minutes of regional ischaemia followed by 
10 minutes of reperfusion was performed prior to 30 minutes of index ischaemia. 
Similarly, S1P (10 nmol/L) was infused for 7 minutes followed by 10 minutes 
washout prior to the 30 minutes of index ischaemia in the S1P preconditioning group. 
Furthermore, in the S1P and AG490 preconditioning group, AG490 (100 nmol/L) was 
infused for 3 minutes before the concurrent 7 minutes infusion with S1P. Thereafter, 
only AG490 was infused for the next 5 minutes (hence a total of 15 min of AG490 
was infused), followed by 5 minutes of washout. Finally the 30 min of index 
ischaemia was commenced followed by 120 minutes of reperfusion. Infarct size was 
assessed in all hearts at the end of the reperfusion period (Figure 11).  
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Ischaemic control  
 
 
 
1. Ischaemic preconditioning  
 
 
 
2. S1P preconditioning  
 
 
 
3. S1P and AG490 preconditioning 
 
 
 
 
 
 
            S1P   AG490   Infarct size assessment Western blot sampling  
 
Figure 11: Schematic diagram of isolated rat hearts undergoing a 
preconditioning protocol 
See text for details. 
 
3.3.2.2 Postconditioning protocol in isolated rat hearts 
3.3.2.2.1 Regional ischaemia 
 
The ischaemic control group in isolated rat hearts were subjected to 30 minutes of 
stabilisation, 30 minutes of regional ischaemia followed by 120 minutes of 
reperfusion. In the ischaemic postconditioning group, the postconditioning stimulus 
was performed immediately at the onset of reperfusion and consisted of 6 cycles of 
alternating 10 seconds reperfusion and 10 seconds of ischaemia. The ischaemic 
postconditioning and A490 group received AG490 (100 nmol/L) perfused for first 15 
minutes of reperfusion together with the postconditioning stimulus. An AG490 control 
30 min 30 min 120 min 
Ischaemia Reperfusion Stabilisation 
5’    15’ 
Reperfusion Stabilisation Ischaemia 
5’    15’ 
Reperfusion Stabilisation Ischaemia 
5’    15’ 
Reperfusion Stabilisation Ischaemia 
5’    15’ 
Ischaemic  
preconditioning 
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group consisted of AG490 perfused for first 15 minutes of reperfusion only. At the 
end of each experiment, isolate rat hearts underwent infarct size assessment (Figure 
12). 
 
1. Ischaemic control  
 
 
 
2. Ischaemic postconditioning 
 
 
 
3. Ischaemic postconditioning and AG490 
 
 
 
 
 
4. AG490 control 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Schematic diagram of isolated rat hearts undergoing 
postconditioning and regional ischaemia 
See text for details. 
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Ischaemia Reperfusion Stabilisation 
Ischaemia Reperfusion Stabilisation 
Ischaemia Reperfusion Stabilisation 
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AG490 Infarct size assessment 
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3.3.2.2.2. Global ischaemia 
 
In another set of experiments, the ischaemic control group in isolated rat hearts were 
subjected to 30 minutes of stabilisation, 30 minutes of global ischaemia followed by 
30 minute of reperfusion. In the ischaemic postconditioning group, the 
postconditioning stimulus was performed immediately at the onset of reperfusion and 
consisted of 6 cycles of alternating 10 seconds reperfusion and 10 seconds of 
ischaemia. The ischaemic postconditioning and AG490 group received AG490 (100 
nmol/L) perfused for first 15 minutes of reperfusion together with postconditioning 
stimulus. An AG490 control group consisted of AG490 perfused for 15 minutes at the 
onset of reperfusion. During the experiment, haemodynamic parameters such as 
heart rate, coronary flow rate and left ventricular developed pressures were recorded 
(Figure 13). 
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1. Ischaemic control  
 
 
 
2. Ischaemic postconditioning 
 
 
 
3. Ischaemic postconditioning and AG490 
 
 
 
 
 
4. AG490 control 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Schematic diagram of isolated rat hearts undergoing 
postconditioning and global ischaemia 
See text for details. 
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3.3.2.3. Infarct size assessment 
 
Hearts which underwent regional ischaemia had the coronary artery re-occluded at 
the end of the protocol and 0.5ml of 2% Evans blue was perfused through the heart 
to delineate the area of the heart affected by the occlusion of the left descending 
coronary artery. All hearts were frozen for 24 hours, cut into 2mm thick slices, 
incubated in sodium phosphate buffer containing 1% w/v triphenyltetrazolium 
chloride (TTC) at 37°C, ph 7.4 for 15 min to visualize the area at risk of cardiac 
damage, with the remaining unstained area denoting the infarcted area in which the 
heart had irreversible died. Infarct and risk zone areas were determined with 
planimetry (Summa Sketch II; Summa Graphics) and infarct size was expressed as a 
percentage of the area at risk. 
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3.4  Western blots 
 
Western blotting was used to quantify changes, if any, in the level of protein 
expression as a result of preconditioning and postconditioning. Since two models 
were used, namely fibroblasts and the isolated rat heart model, two similar methods 
of protein extraction were used.  
 
3.4.1 Protein extraction from fibroblasts 
 
At the end of the preconditioning protocol and before the 8.5 hours of ischaemia,  
fibroblasts were immediately washed with 5ml cold phosphate buffered saline (PBS) 
and incubated in 5ml 0.25% trypsin for 5 minutes at 37°C. A further 9ml of cold PBS 
was added and placed in an eppendorf that was centrifuged at 1200 rpm for 5 
minutes at 4°C. The supernatant was discarded, the cell pellet was resuspended in 
1ml cold PBS and transferred to another eppendorf.  
 
3.4.1.1  Cytosolic extract 
 
Eppendorfs were centrifuged for 15 seconds at 8000rpm at 4°C, followed by removal 
of the supernatant and resuspension of the precipitate in 150μl of lysis buffer 
containing 10mM HEPES, 10mM KCL, 0.1mM EDTA and 0.1mM EGTA. The 
suspension was left on ice for 15 minutes before the addition of 30μl of 10% Igepal 
CA-630 (diluted in dH2O, Sigma) followed by brief vortexing and 30 seconds of 
centrifugation at 14000rpm at 4°C. The resulting supernatant contained the cytosolic 
protein extract and was appropriately aliquoted into eppendorfs. It was stored at  
-80°C until needed. 
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3.4.1.2  Nuclear extract 
 
The pellet was resuspended in 50μl of nuclear lysis buffer containing 20mM HEPES, 
400mM NaCl, 1mM EDTA, 1mM EGTA and 20% glycerol. The suspension was 
incubated in a shaker at 4°C for 15 minutes. After a brief vortex, it was returned to 
the shaker for a further 15 minutes. The tubes were then centrifuged at 14000rpm for 
5 minutes at 4°C. The resulting supernatant contained the nuclear protein extract, 
and thus appropriately aliquoted into eppendorfs.  It was stored at -80°C, until 
needed. 
 
3.4.2  Protein extraction from rat hearts 
 
Rat hearts were harvested either immediately after the S1P preconditioning stimulus, 
or 5 or 15 minutes after reperfusion following the index ischaemia. Hearts were 
quickly removed from the experiemental rig, placed in ice cooled Krebs-Henseleit 
buffer whilst the atria were rapidly removed, separated into left and right ventricle 
and both ventricles freeze clamped in liquid nitrogen. The frozen rat ventricles were 
then stored at -80°C for later use. 
 
Since the left ventricle is mainly affected during regional ischaemia, only the tissue 
from the rat left ventricle was used. All frozen hearts wrapped in aluminium foil were 
pulverized under liquid nitrogen with a hammer and approximately 200mg of 
powdered tissue was placed into 900µl of lysis buffer (20mM HEPES, 2.5mM 
MgCL2, 100μM EDTA, 20mM β- glycerophosphate, 0.5% Triton X-100, 500μM 
dithiothreitol (DTT), 100µM NaVO4, 1mM phenylmethylsulfonyl fluoride (PMSF) and 
75mM NaCl). The suspension of powered tissue in lysis buffer was ultrasonically 
homogenised by Polytron (Brinkmann Instruments, Canada) for 5 seconds. 
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3.4.2.1  Cytosolic extract  
 
The homogenised samples were centrifuged at 10000g for 5 minutes at 4°C. The 
supernatant was decanted into another tube and represented the cytosolic extract 
(Williams et al., 2000). 
 
3.4.2.2  Nuclear extract 
 
The remaining pellet was resuspended in 500μl of lysis buffer (20mM HEPES, 
2.5mM MgCL2, 100μM EDTA, 20mM β- glycerophosphate, 1% Triton X-100, 500μM 
DTT, 100µM NaVO4, 1mM PMSF and 75mM NaCl). The suspension was centrifuged 
at 15000g for 30min 4°C with the supernatant decanted was into another tube and 
represented the nuclear extract (Williams et al., 2000).  
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3.4.3  Protein quantification  
 
The Lowry Assay was used to quantify the concentration of proteins (Lowry et al., 
1951). The bovine serum albumin (BSA) standard curve ranged from a concentration 
of 5-200mg/l. Protein samples were added to 1 ml of distilled water in a 1:200 
volume ratio.  1ml of Solution A containing a composite of three solutions in equal 
volumes; 5-cyano-2,3-ditolyl tetrazolium chloride (CTC) reagent, 10% sodium 
dodecyl sulfate (SDS) and 50 µM sodium hydroxide (NaOH) was added to each 
tube.  CTC reagent contained 2% (w/v) sodium carbonate (Na2CO3) mixed in a ratio 
100:1:1 (v:v:v) with 1% (w/v) copper sulphate (CuSO4.5H2O) and 1% (w/v) di-
potassium tartrate hemihydrate (C4H4K2O6.0.5H2O).  After 10 minutes at room 
temperature, 0.02 N Folin phenol reagent was added to each tube.  Following 30 
minutes of incubation, the absorbance was measured with a spectrometer at 250nm. 
 
3.4.4  SDS PAGE of extracted proteins  
 
Lysates were diluted in Laemmli sample buffer, boiled for 5 min. 20μg of proteins 
were separated on 10% sodium dodecyl sulphate (SDS) PAGE using standard Bio-
Rad Mini-PROTEAN ІІ System for two hours at 0.2volts and transferred to 
nitrocellulose membrane (Amersham Bioscience Hybond P RPN 303F).  
 
3.4.5  Immuno-blotting and detection  
 
The membranes were stained with a Ponceau Red stain (Ponceau S solution Sigma, 
USA P7170) and the membrane was blocked with 5% of milk in tris-buffered saline 
(TBS-Tween) (0.1% Tween).  
 
All blots were probed with phosphorylated states of STAT-3 (Tyr 705 and Ser 727), 
BAD (Ser 136) and FoxO (Ser 318/321) and their respective total levels of STAT-3, 
BAD and FoxO. After primary antibody incubation, blots were washed off with TBS -
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T (0.1% Tween) 3 times for 5 minutes and probed with their respective secondary 
antibody labelled with horseradish peroxidase.  
 
All blots were developed and digitally captured in the Genegnome (SynGene, 
Cambridge, UK). All blots were normalised to either β-actin or ponceau, and the 
phosphorylated states of proteins were normalised by division with their respective 
total state. Relative densitometry was determined with GeneSnap and GeneTools 
software (SynGene, Cambridge, UK). 
 
3.5.  Chemicals and pharmacological agents 
 
Unless otherwise stated, all chemicals were obtained from Sigma-Aldrich Chemicals, 
Germany. Similarly, all antibodies were from Cell Signalling Technology, USA. 
 
3.6  Statistical analysis 
 
All data were expressed as the mean ± SEM.  Statistical significance was 
determined by a student T-test when appropriate or a one way analysis of variance 
(ANOVA) with a Student Newman-Keul post hoc test (Graph Pad Instat). *p< 0.05 
was considered significant. 
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Chapter Four: Results 
4.1 Cytoprotective effect of S1P preconditioning 
4.1.1.  Role of S1P preconditioning in fibroblasts  
 
To explore the protective effect of S1P preconditioning, we initially conducted our 
studies in Mouse L cells. After 8.5 hours of simulated ischaemia, the survival rate 
was 30.0% (all data normalised to ischaemic control). This data was consistent with 
the literature (Lecour et al., 2006). S1P preconditioning significantly improved cell 
survival as compared to its respective ischaemic control at the end of the simulated 
ischaemia (38.1±1.5% vs. 30.0±0.0%, p<0.05 vs. control). Co-treatment of AG490 
with S1P abolished the effect of S1P as compared to the control group at the end of 
simulated ischaemia (29.9±2.7%, ns vs. control). Surprisingly AG490 itself produced 
a protective effect as compared to the control group after simulated ischaemia 
(40.0±2.4%, p<0.05 vs. control, n=2) (Figure 14). 
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Figure 14: S1P increases cell survival in fibroblasts 
IC=ischaemic control, S1P=sphingosine 1 phosphate, AG=AG490. * p<0.05 vs. IC. n≥5 per group 
except AG where n=2. 
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4.1.2. Role of S1P preconditioning on tyrosine phosphorylated 
STAT-3 in fibroblasts 
 
Since S1P preconditioning significantly improved cell survival, we explored if the 
protective effect could be accounted by the activation and hence phosphorylation of 
tyrosine STAT-3. 
 
In the cytosolic fraction, S1P preconditioning significantly decreased tyrosine 
phosphorylated STAT-3 as compared to its respective ischaemic control at the end 
of simulated ischaemia (1.4±0.1A.U. vs. 0.6±0.1A.U., p<0.05 vs. control). Co-
treatment of AG490 with S1P abolished the effect of S1P (1.1±0.2A.U., ns vs. 
control) and AG490 alone (1.5±0.2A.U., ns vs. control), had no effect on tyrosine 
phosphorylated STAT-3 as compared with the control group at the end of simulated 
ischaemia. 
 
In the nuclear fraction, S1P preconditioning did not significantly affect tyrosine 
phosphorylated STAT-3 as compared to its respective ischaemic control at the end 
of simulated ischaemia (1.1±0.2A.U. vs. 0.8±0.1A.U., ns vs. control). Co-treatment of 
AG490 with S1P (1.2±0.2A.U., ns vs. control) and AG490 alone (1.0±0.1A.U., ns vs. 
control), had no effect on tyrosine phosphorylated STAT-3 as compared with the 
control group at the end of simulated ischaemia (Figure 15). 
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Figure 15: Tyrosine phosphorylated STAT-3 in the cytosol and nuclear fraction 
Significant decrease in cytosolic tyrosine phosphorylated STAT-3 with S1P preconditioning compared 
to ischaemic control.  Hearts were harvested 15 minutes after S1P pre-treatment and hence prior to 
the index ischaemia. IC=ischaemic control, S1P=sphingosine 1 phosphate, AG=AG490, P-STAT-
3=phosphorylated STAT-3, T-STAT-3=Total STAT-3. *p<0.05 vs. control. n=4 per group. 
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4.2 Cardioprotective effect of S1P preconditioning  
4.2.1 Role of S1P preconditioning on haemodynamic parameters 
4.2.1.1 Regional ischaemia 
 
After 30 minutes of regional ischaemia and 120 minutes of reperfusion, the LVDP in 
the ischaemic control group was 46±8mmHg. This data was consistent with the 
literature (Lecour et al., 2005a). S1P preconditioning did not significantly change 
LVDP as compared to its respective ischaemic control at the end of reperfusion 
(45±7mmHg vs. 46±8mmHg, ns vs. control). Co-treatment of AG490 with S1P 
(67±3mmHg, ns vs. control) and AG490 alone (66±4mmHg, ns vs. control), had no 
effect on LVDP as compared with the control group at the end of reperfusion  
 
S1P preconditioning did not significantly change h art rate as compared to its 
respective ischaemic control at the end of reperfusion (268±28 beats/minute vs. 
293±11 beats/minute, ns vs. control). Co-treatment of AG490 with S1P (283±21 
beats/minute, ns vs. control) and AG490 alone (257±24 beats/minute, ns vs. control), 
had no effect on heart rate as compared with the control group at the end of 
reperfusion. 
 
SIP preconditioning did not significantly change coronary flow rate as compared to 
its respective ischaemic control at the end of reperfusion (5.9±0.8 ml/minute vs. 
7.8±1.9 ml/minute, ns vs. control). Co-treatment of AG490 with S1P (5.8 ±0.7 
ml/minute, ns vs. control) and AG490 alone (5.0±0.2 ml/minute, ns vs. control), had 
no effect on coronary flow rate as compared with the control group at the end of 
reperfusion (Table 1).  
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Table 1: Haemodynamic parameters of isolated rat hearts exposed to regional 
ischaemia and S1P preconditioning 
Preischaemia Reperfusion  Reperfusion  
    5 minutes  120 minutes 
LVDP (mmHg) 
IC   86 ± 7   69 ± 8   46 ± 8 
S1P  83 ± 5   71 ± 7   45 ± 7 
S1P+AG  99 ± 3   81 ± 3   67 ± 3  
AG   92 ± 5   75 ± 4   66 ± 4 
 
Heart rate (beats/minute) 
IC   287 ± 18  270 ± 14  293 ± 11 
S1P  280 ± 20  288 ± 42  268 ± 28 
S1P+AG  273 ± 17  297 ± 18  283 ± 21 
AG   293 ± 18  240 ± 15  257 ± 24 
 
Flow (ml/minute) 
IC   10.8 ± 1.4  11.2 ± 1.7  7.8 ± 1.9 
S1P    9.7 ± 0.9    9.8 ± 0.8  5.9 ± 0.8 
S1P+AG    9.8 ± 1.0    8.4 ± 0.6  5.8 ± 0.7 
AG     8.1 ± 0.3    8.2 ± 0.2  5.0 ± 0.2 
 
Parameters measured prior to ischaemia (preischaemia) and at 5 minutes or 120 minutes after 
reperfusion respectively. IC=ischaemic control, S1P=sphingosine 1 phosphate, AG=AG490. n=6 per 
group. 
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4.2.2 Role of S1P preconditioning on infarct size  
 
After 30 minutes of regional ischaemia and 2 hours of reperfusion, the infarct size in 
the ischaemic control group was 25.8±3.1%. S1P preconditioning significantly 
decreased infarct size (4.6±1.4%, p<0.05 vs. control), an effect consistent with the 
literature (Vessey et al., 2008b, Vessey et al., 2009b, Lecour et al., 2002). Co-
treatment of AG490 with S1P abolished the effect of S1P (29.5±4.0%. ns vs. control) 
and AG490 alone (25.7±5.9%, ns vs. control), had no effect on infarct size as 
compared with the control group at the end of reperfusion. All regional ischaemia 
data were normalised to the area at risk (data not shown). 
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Figure 16: S1P preconditioning decreases infarct size and abolished with 
AG490 treatment 
IC=ischaemic control, S1P=sphingosine 1 phosphate, AG=AG490. *p<0.05 vs. control. n=6 per group. 
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4.2.3 Role of S1P preconditioning on STAT-3/BAD/FoxO activation 
 
Since S1P preconditioning decreased infarct size, we explored if the protective effect 
could be accounted by the activation of STAT-3 and its possible downstream 
effectors including BAD and FoxO. Western blot sampling initially occurred at 5 
minutes during reperfusion in order to correctly identify the time period where one 
could detect changes in the proposed downstream effectors of S1P. Previous 
research from this lab has demonstrated changes in STAT-3 within 5 minutes of 
reperfusion (Lecour et al., 2005b). However in the setting of S1P preconditioning, 
other researchers have sampled protein levels after 40 minutes of reperfusion after 
global ischaemia (Vessey et al., 2009a).  
 
Subsequent to the results of sampling at 5 minutes, we repeated the experiment at 
15 minutes of reperfusion which has been used by many researchers as another 
optimal time period to detect changes in protein expression levels during reperfusion 
(Hausenloy et al., 2005, Fuglesteg et al., 2008).  
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4.2.3.1.1 Role of S1P preconditioning on tyrosine phosphorylated STAT-3 
at 5 minutes of reperfusion 
 
After 30 minutes of regional ischaemia and at 5 minutes of reperfusion, S1P 
preconditioning did not significantly change tyrosine phosphorylated STAT-3 as 
compared to its respective ischaemic control in the cytosolic fraction (1.3±0.3A.U. vs. 
1.2±0.1A.U., ns vs. control). In the nuclear fraction, S1P preconditioning tended to 
decrease tyrosine phosphorylated STAT-3 as compared to its respective ischaemic 
control at 5 minutes of reperfusion (1.0±0.1A.U. vs. 1.6±0.3A.U., p=0.07). However 
such a trend should be interpreted cautiously as no comparison was made with the 
AG490 co-treatment or AG490 alone (Figure 17). 
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Figure 17: Tyrosine phosphorylated STAT-3 in cytosolic and nuclear fractions 
in isolated rat hearts undergoing regional ischaemia at 5 minutes of 
reperfusion 
IC=ischaemic control, S1P=sphingosine 1 phosphate, AG=AG490. *p<0.05 vs. control. n=6 per group. 
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4.2.3.1.2. Role of S1P preconditioning on serine phosphorylated STAT-3 at 
5 minutes of reperfusion 
 
S1P preconditioning did not significantly change serine phosphorylated STAT-3 as 
compared to its respective ischaemic control in the cytosolic fraction (1.1±0.2A.U. vs. 
1.2±0.3A.U., ns vs. control) or in the nuclear fraction at 5 minutes of reperfusion 
(1.5±0.4A.U. vs. 1.5±0.3A.U., ns vs. control) (Figure 18). 
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Figure 18: Serine phosphorylated STAT-3 in cytosolic and nuclear fractions of 
isolated rat hearts undergoing regional ischaemic at 5 minutes of reperfusion 
IC=ischaemic control, S1P=sphingosine 1 phosphate, P-STAT-3=phosphorylated STAT-3, T-STAT-
3=Total STAT-3. n=6 per group. 
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4.2.3.1.3 Role of S1P preconditioning on phosphorylated FoxO at 5 
minutes of reperfusion 
 
S1P preconditioning did not significantly change phosphorylated FoxO as compared 
to its respective ischaemic control in the cytosolic fraction (0.5±0.1A.U. vs. 
0.8±0.2A.U., ns vs. control) or in the nuclear fraction at 5 minutes of reperfusion 
(1.3±0.3A.U. vs. 0.9±0.2A.U., ns vs. control) (Figure 19).  
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Figure 19: Phosphorylated FoxO in cytosolic and nuclear fractions in isolated 
rat hearts undergoing regional ischaemia at 5 minutes of reperfusion 
IC=ischaemic control, S1P=sphingosine 1 phosphate, P-STAT-3=phosphorylated STAT-3, T-STAT-
3=Total STAT-3. n=6 per group. 
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4.2.3.1.3 Role of S1P preconditioning on phosphorylated BAD at 5 minutes 
of reperfusion 
 
In addition to FoxO, BAD was another possible downstream effector, whereby 
phosphorylation of proapoptotic BAD results in cardioprotection (Murphy, 2004). S1P 
preconditioning tended to decrease phosphorylated BAD as compared to its 
respective ischaemic control in the cytosolic fraction (1.6±0.4A.U vs. 0.7±0.3A.U., 
p=0.08). Again, such a trend should be interpreted cautiously as no comparison was 
made with the AG490 co-treatment or AG490 alone. In the nuclear fraction, S1P 
preconditioning did not significantly change phosphorylated BAD as compared to its 
respective ischaemic control at 5 minutes of reperfusion (1.4±0.4A.U. vs. 
1.5±0.4A.U., ns vs. control) (Figure 20).  
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Figure 20: Phosphorylated BAD in cytosolic and nuclear fractions in isolated 
rat hearts undergoing regional ischaemia at 5 minutes of reperfusion 
IC=ischaemic control, S1P=sphingosine 1 phosphate, P-STAT-3=phosphorylated STAT-3, T-STAT-
3=Total STAT-3. n=6 per group. 
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4.2.4.1.1 Role of S1P preconditioning on tyrosine phosphorylated STAT-3 
at 15 minutes of reperfusion 
 
Similar to the previous experiments conducted at 5 minutes of reperfusion, tyrosine 
phosphorylated STAT-3 levels were examined at 15 minutes of reperfusion. In the 
cytosolic fraction, S1P preconditioning did not significantly change tyrosine 
phosphorylated STAT-3 as compared to its respective ischaemic control at 15 
minutes of reperfusion (1.8±0.4A.U. vs. 1.6±1.0A.U., ns vs. control). Co-treatment of 
AG490 with S1P (1.6±1.0A.U., ns vs. control) and AG490 alone (1.4±0.7A.U., ns vs. 
control), had no effect on tyrosine phosphorylated STAT-3 as compared with the 
control group at 15 minutes of reperfusion. 
 
In the nuclear fraction, S1P preconditioning did not significantly change tyrosine 
phosphorylated STAT-3 as compared to its respective ischaemic control at 15 
minutes of reperfusion (1.2±0.4A.U. vs. 0.5±0.1A.U., ns vs. control). Co-treatment of 
AG490 with S1P (0.7±0.3A.U., ns vs. control) and AG490 alone (1.1±0.4A.U., ns vs. 
control), had no effect on tyrosine phosphorylated STAT-3 as compared with the 
control group at 15 minutes of reperfusion (Figure 21). 
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Figure 21: Tyrosine phosphorylated STAT-3 in cytosolic and nuclear fractions 
in isolated rat hearts undergoing regional ischaemia at 15 minutes of 
reperfusion 
IC=ischaemic control, S1P=sphingosine 1 phosphate, AG=AG490, P-STAT-3=phosphorylated STAT-
3, T-STAT-3=Total STAT-3. n=4 per group. 
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4.2.4.1. 2 Role of S1P preconditioning on serine phosphorylated STAT-3 at 
15 minutes of reperfusion 
 
Similar to the previous experiments conducted at 5 minutes of reperfusion, serine 
phosphorylated STAT-3 levels were examined at 15 minutes of reperfusion. In the 
cytosolic fraction, S1P preconditioning did not significantly change phosphorylated 
serine STAT-3 as compared to its respective ischaemic control at 15 minutes of 
reperfusion (1.1±0.3A.U. vs. 1.4±0.4A.U., ns vs. control). Co-treatment of AG490 
with S1P (0.6±0.3A.U., ns vs. control) or AG490 alone (0.9±0.4A.U., ns vs. control), 
had no effect of serine phosphorylated STAT-3 as compared with the control group 
at 15 minutes of reperfusion. 
 
In the nuclear fraction, S1P preconditioning did not significantly change serine 
phosphorylated STAT-3 as compared to its respective ischaemic control at 15 
minutes of reperfusion (0.7±0.3A.U. vs. 0.5±0.4A.U., ns vs. control). Co-treatment of 
AG490 with S1P (0.9±0.5A.U., ns vs. control) or AG490 alone (0.8±0.6A.U., ns vs. 
control), had no effect on serine phosphorylated STAT-3 as compared with the 
control group at 15 minutes of reperfusion (Figure 22). 
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Figure 22: Serine phosphorylated STAT-3 in cytosolic and nuclear fractions in 
isolated rat hearts undergoing regional ischaemia at 15 minutes of reperfusion 
IC=ischaemic control, S1P=sphingosine 1 phosphate, AG=AG490, P-STAT-3=phosphorylated STAT-
3, T-STAT-3=Total STAT-3. n=4 per group. 
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4.2.4.1. 3 Role of S1P preconditioning on phosphorylated FoxO at 15 
minutes of reperfusion 
 
Similar to the previous experiments conducted at 5 minutes of reperfusion, 
phosphorylated FoxO levels were examined at 15 minutes of reperfusion. In the 
cytosolic fraction, S1P preconditioning did not significantly change phosphorylated 
FoxO as compared to its respective ischaemic control at 15 minutes of reperfusion 
(1.4±0.9A.U. vs. 1.0±0.4A.U., ns vs. control). Co-treatment of AG490 with S1P 
(2.0±0.9A.U., ns vs. control) or AG490 alone (1.3±0.4A.U., ns vs. control), had no 
effect on phosphorylated FoxO as compared with the control group at 15 minutes of 
reperfusion. 
 
In the nuclear fraction, S1P preconditioning did not significantly change 
phosphorylated FoxO as compared to its respective ischaemic control at 15 minutes 
of reperfusion (1.5±0.8A.U. vs. 1.5±0.5A.U., ns vs. control). Co-treatment of AG490 
with S1P (1.2±0.5A.U., ns vs. control) or AG490 alone (1.5±0.4A.U., ns vs. control),  
had no effect on phosphorylated FoxO as compared with the control group at 15 
minutes of reperfusion (Figure 23). 
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Figure 23: Phosphorylated FoxO in cytosolic and nuclear fractions in isolated 
rat hearts undergoing regional ischaemia at 15 minutes reperfusion 
IC=ischaemic control, S1P=sphingosine 1 phosphate, AG=AG490, P-STAT-3=phosphorylated STAT-
3, T-STAT-3=Total STAT-3. n=4 per group. 
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4.3  Ischaemic postconditioning protects the heart 
4.3.1  Role of ischaemic postconditioning in hearts subjected to 
regional ischaemia 
4.3.1.1 Haemodynamic parameters 
 
After 30 minutes of regional ischaemia and 120 minutes of reperfusion, the LVDP in 
the ischaemic control group was 56±4mmHg. This data was consistent with the 
literature (van Vuuren et al., 2008, Lee et al., 2010). Ischaemic postconditioning did 
not significantly change LVDP as compared to its respective ischaemic control at the 
end of reperfusion (67±3mmHg vs. 56±4mmHg, ns vs. control). Co-treatment of 
AG490 with ischaemic postconditioning (49±5mmHg, ns vs. control) and AG490 
alone (58±4mmHg, ns vs. control), had no effect on LVDP as compared with the 
control group at the end of reperfusion. 
 
Ischaemic postconditioning did not significantly change heart rate as compared to its 
respective ischaemic control at the end of reperfusion (292±8 beat/minute vs. 
283±13 beats/minute, ns vs. control). Co-treatment of AG490 with ischaemic 
postconditioning (253±12 beats/minute, ns vs. control) and AG490 alone (257±24 
beats/minute, ns vs. control), had no effect on heart rate as compared with the 
control group at the end of reperfusion. 
 
Ischaemic postconditioning did not significantly change coronary flow rate as 
compared to its respective ischaemic control at the end of reperfusion (8.0±0.6 
ml/minute vs. 6.2±0.7 ml/minute, ns vs. control). Co-treatment of AG490 with 
ischaemic postconditioning (5.9±0.6 ml/minute, ns vs. control) and AG490 alone 
(5.0±0.2 ml/minute, ns vs. control), had no effect on coronary flow rate as compared 
with the control group at the end of reperfusion (Table 2). 
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Table 2: Haemodynamic parameters of isolated rat hearts exposed to regional 
ischaemia and ischaemic postconditioning 
 
   Preischaemia Reperfusion   Reperfusion 
5 minutes   120 minutes 
LVDP (mmHg) 
IC   77 ± 2   70 ± 3   56 ± 4 
Postcon  81 ± 4   75 ± 3   67 ± 3 
Postcon+AG 90 ± 4   75 ± 8   49 ± 5 
AG   94 ± 8   80 ± 7   58 ± 4 
 
Heart rate (beats/minute) 
IC   314 ± 14  257 ± 29  283 ± 13 
Postcon  307 ± 13  292 ± 10  292 ±   8 
Postcon+AG 316 ± 12  253 ±   7  253 ± 12 
AG   284 ± 15  267 ± 28  229 ± 21  
 
Flow (ml/minute) 
IC     9.1 ± 0.4    8.1 ± 0.6  6.2 ± 0.7 
Postcon  10.3 ± 0.8    9.8 ± 0.7  8.0 ± 0.6 
Postcon+AG 10.7 ± 0.7    9.8 ± 0.6  5.9 ± 0.6 
AG    10.7 ± 1.3  10.0 ± 0.8  6.1 ± 0.9 
 
Parameters measured prior to ischaemia (preischaemic) and at 5 minutes or 120 minutes after 
reperfusion respectively. AG490 (100 nmol/L), LVDP=left ventricular developed pressure, 
IC=ischaemic control, postcon=postconditioning, AG=AG490. n=6 per group. 
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4.3.1.2  Infarct size 
 
After 30 minutes of regional ischaemia and 2 hours of reperfusion, the infarct size in 
the ischaemic control group was 32±5%. Ischaemic postconditioning with 6 cycles of 
alternating 10 seconds of reperfusion and 10 seconds of ischaemia significantly 
decreased infarct size (11±1%, p<0.05 vs. control), an effect consistent with the 
literature (You et al., 2011, Zhao et al., 2003). Co-treatment of AG490 with ischaemic 
postconditioning abolished the effect of ischaemic postconditioning (26±4%, ns vs. 
control) and AG490 alone (33±7%, ns vs. control), had no effect on infarct size as 
compared with the control group at the end of reperfusion (Figure 24). All regional 
ischaemia data were normalised to the area at risk (data not shown). 
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Figure 24: Ischaemic postconditioning decreases infarct size and abolished 
with AG490 treatment 
IC=ischaemic control, AG=AG490. *p<0.05 vs. control. n=6 per group. 
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4.3.2 Role of ischaemic postconditioning in hearts subjected to 
global ischaemia 
4.3.2.1. Haemodynamic parameters 
 
After 30 minutes of global ischaemia and 30 minutes of reperfusion, the LVDP was 
25±3mmHg. Ischaemic postconditioning significantly increased LVDP (52±5mmHg 
vs. 25±3mmHg, p<0.01 vs. control), an effect consistent with the literature (Inamura 
et al., 2010, Jin et al., 2008). Co-treatment of AG490 with ischaemic postconditioning 
abolished the effect of ischaemic postconditioning (36±6mmHg, ns vs. control) and 
AG490 alone (21±4mmHg, ns vs. control), had no effect on LVDP as compared with 
the control group at the end of reperfusion. 
 
Ischaemic postconditioning did not significantly change heart rate as compared to its 
respective ischaemic control at the end of reperfusion (248±15 beats/minute vs. 
260±25 beats/minute, ns vs. control). Co-treatment of AG490 with ischaemic 
postconditioning (207±15 beats/minute, ns vs. control) and AG490 alone (273±35 
beats/minute), had no effect on heart rate as compared with the control group at the 
end of reperfusion. 
 
Ischaemic postconditioning did not significantly change coronary flow rate as 
compared to its respective ischaemic control at the end of reperfusion (8.3±2.0 
ml/minute vs. 7.0±1.4ml/minute, ns vs. control). Co-treatment of AG490 with 
ischaemic postconditioning (9.8±1.1ml/minute, ns vs. control) and AG490 alone 
(8.0±0.6 ml/minute), had no effect on coronary flow rate as compared with the 
control group at the end of reperfusion (Table 3).  
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Table 3: Hemodynamic parameters of isolated rat hearts exposed to global 
ischaemic postconditioning 
Pre-ischemic  Reperfusion  Reperfusion 
   5 minutes  30 minutes 
LVDP (mmHg) 
IC      80 ± 1   22 ± 4   25 ± 3 
Postcon     83 ± 3   40 ± 8 *  52 ± 5 * 
Postcon+AG 83 ± 4   25 ± 2   36 ± 6 
AG   87 ± 6   20 ± 3   21 ± 4 
 
Heart rate (beats/minute) 
IC      313 ± 22  220 ± 38  260 ± 25 
Postcon    304 ± 10  250 ± 44  248 ± 15 
Postcon+AG 333 ±   8  200 ± 38  207 ± 16 
AG   307 ± 13  180 ± 47  273 ± 35 
 
Flow (ml/minute) 
IC     12.4 ± 1.6    9.0 ± 1.2  7.0 ± 1.4 
Postcon  13.3 ± 1.3  10.0 ± 1.2  8.3 ± 2.0 
Postcon+AG 12.0 ± 0.6    7.0 ± 1.0  9.8 ± 1.1 
AG   12.7 ± 0.7    7.0 ± 1.0  8.0 ± 0.6 
 
 
Parameters measured prior to ischemia (pre-ischemic), 5 minutes and 30 minutes after reperfusion. 
AG490 (100 nmol/L). LVDP=left ventricular developed pressure, postcon=postconditioning, 
AG=AG490, * p<0.01 vs. IC, n≥4 per group. 
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4.3.2.2. Role of ischaemic postconditioning on rate pressure product (RPP) 
 
After 30 minutes of global ischaemia, ischaemic postconditioning did significantly 
raise the rate pressure product (RPP) as compared to its respective ischaemic 
control at 5 minutes (48±1% vs. 19±3%, p<0.05 vs. control) and at 30 minutes of 
reperfusion (51±5% vs. 26±4%, p<0.05 vs. control). This data was consistent with 
the literature (Bopassa et al., 2006, Lee et al., 2010). Co-treatment of AG490 with 
ischaemic postconditioning abolished the effect of ischaemic postconditioning as 
compared to the control group at 5 minutes (16±4%, ns vs. control) and at 30 
minutes of reperfusion (26±7%, ns vs. control). AG490 alone did not significantly 
change RPP as compared with control group at 5 minutes (13±5%, ns vs. control) 
and at 15 minutes of reperfusion (21±3%, ns vs. control) (Figure 25). 
0
10
20
30
40
50
60
AGPostcon
+
AG
PostconICPostcon
+
AG
AGPostconIC
30 minutes5 minutes
 
R
a
te
 p
re
s
s
u
re
 p
ro
d
u
c
t 
(%
 o
f 
b
a
s
e
lin
e
)
 
Figure 25: Postconditioning improves the rate pressure product at 5 and 30 
minutes after reperfusion in isolated rat hearts after global ischaemia 
IC=ischaemic control, postcon=postconditioning, AG=AG490. *p<0.05 vs. control. n≥4 per group.  
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4.3.2.3  Role of ischaemic postconditioning on tyrosine phosphorylated 
STAT-3 at 15 minutes of reperfusion 
 
After 30 minutes of global ischaemia and at 15 minutes of reperfusion, ischaemic 
postconditioning did significantly decrease tyrosine phosphorylated STAT-3 as 
compared to its respective ischaemic control in the cytosolic fraction (0.5±0.1A.U. vs. 
1.6±0.3A.U., p<0.05 vs. control). In the nuclear fraction, ischaemic postconditioning 
concurrently increase tyrosine phosphorylated STAT-3 as compared to its respective 
ischaemic control at 15 minutes of reperfusion (2.5±0.2A.U. vs. 1.3±0.4A.U., p<0.05 
vs. control) (Figure 26). 
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Figure 26: Tyrosine phosphorylated STAT-3 in postconditioning isolate rat 
hearts including cytosolic and nuclear fractions 
IC=ischaemic control, postcon=postconditioning, P-STAT-3=phosphorylated STAT-3, T-STAT-3=Total 
STAT-3. *p<0.05 vs. control. n=4 per group.  
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Chapter Five: Discussion 
 
The results of this study have demonstrated that S1P preconditioning can mimic 
ischaemic preconditioning to result in cytoprotection in fibroblasts and 
cardioprotection in the isolated rat heart. Furthermore, the cell survival and infarct 
sparing effect of S1P preconditioning was abrogated by AG490, an inhibitor of the 
STAT-3 pathway therefore suggesting a role of STAT-3 in S1P preconditioning. 
Tyrosine phosphorylated STAT-3 was significantly decreased in the cell cytoplasm of 
fibroblasts as measured prior to the index ischaemia. In contrast, STAT-3 displayed 
no significant change after the index ischaemia in the isolated rat hearts. In addition, 
FoxO and BAD displayed no significant change after the index ischaemia suggesting 
that they are not involved as signalling mediators of S1P preconditioning. Ischaemic 
postconditioning could protect the isolated rat heart subjected to regional or global 
ischaemic reperfusion insults and western blot analysis suggest a role for STAT-3 in 
ischaemic postconditioning. 
 
5.1 S1P confers cardioprotection in fibroblasts and isolated rat 
hearts 
 
Using cell culture and isolated rat heart model, our data demonstrate that S1P 
confers cardioprotection against ischaemia reperfusion. Whilst our data is well 
validated in the isolated rat heart model (Vessey et al., 2009b, Tsukada et al., 2007), 
discrepancies arise in the use of the mouse L cell fibroblasts. Previous studies have 
successfully used the L cell line to validate preconditioning (Lecour et al., 2006) 
however it remains unknown how S1P may impact on mouse L cell fibroblasts and if 
these fibroblasts could be comparable to cardiac fibroblasts. 
 
Other studies have noted discrepancies between cardiac fibroblasts and 
cardiomyocytes when studying the cellular effects of S1P. Cardiac fibroblasts 
express more S1P3 receptors than S1P1 and S1P2 receptors. Cardiac fibroblasts 
also exhibit greater sphingosine kinase activity than cardiac myocytes. Hence S1P 
preconditioning will result in a greater increase in endogenous S1P production in 
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fibroblasts as compared to cardiomyocytes respectively. (Landeen et al., 2008). As a 
result, there is a less robust response of exogenous S1P preconditioning in 
fibroblasts as compared to cardiomyocytes most likely because more S1P is already 
available intracellularly in fibroblasts.  
 
Some researchers have used different dosages and vehicles for S1P. Such variation 
in drug concentration is due to the inherent physiological variation of S1P serum 
concentration which normally ranges from 0.2 to 1.1µM (Murata et al., 2000, 
Berdyshev et al., 2005), although these concentrations are most likely to vary during 
pathological conditions. The S1P dose used in our study was 10nM which is in 
agreement with some studies (Jin et al., 2002, Tsukada et al., 2007) but other 
studies used 0.4µM (400nM) (Vessey et al., 2009b). Our concentration was low in 
order to limit known haemodynamic effects such as coronary vasoconstriction via 
S1P2 (Ohmori et al., 2003), bradycardia via S1P3 (Sanna et al., 2004) and decreased 
blood pressure (Karliner, 2004). The vehicle for S1P delivery was DMSO in 
agreement with a previous study (Jin et al., 2002). Interestingly, a recent study used 
reconstituted HDL to demonstrate a cardioprotective effect of S1P against 
doxorubicin induced cardiotoxicity (Frias et al., 2009). 
 
5.1.1 Role of STAT-3 in S1P induced cytoprotection and cardioprotection  
 
S1P is a known preconditioning mimetic using PKCε (Jin et al., 2002) or Akt (Vessey 
et al., 2008a) or ERK1/2 as signalling pathways. In fact, S1P itself has also been 
proposed to mediate the protective effects of TNFα preconditioning, via S1P’s 
involvement in the sphingolipid signalling pathway (Lecour et al., 2002, Vessey et al., 
2009b). However it was unknown whether the JAK/STAT-3 pathway can also 
mediate the effects of S1P preconditioning.  
 
Our data has demonstrated that S1P mediates its cytoprotective and cardio-
protective effects via the JAK/STAT-3 pathway. A link between S1P and JAK/STAT-
3 has recently been demonstrated whereby S1P as part of HDL, protects against 
ischaemia reperfusion via STAT-3 activation (Frias et al., 2009). Furthermore, recent 
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work conducted in our lab showed that S1P can mimic ischaemic postconditioning 
via both STAT-3 and Akt (Somers, 2010).  
 
While our data showed a decrease in cytosolic STAT-3 in fibroblasts exposed to S1P 
preconditioning, a reciprocal change in the nuclear fraction was not observed. STAT-
3 translocation is important because nuclear translocation will result in the 
transcription of genes such as inducible nitric oxide synthase and cyclooxygenase 2 
(Dawn et al., 2004) but cytosolic translocation, or more importantly mitochondrial 
translocation will result in the direct interaction of STAT-3 with mitochondria to 
prevent MPTP closure as currently postulated (Hausenloy et al., 2010b). 
 
To our surprise, AG490 improved cell survival in fibroblasts as compared to the 
ischaemic control.  Such findings are most likely attributed to the low ‘n’ value of 2 for 
the AG490 group as compared to the ischaemic control group of 5 or greater. In 
addition, whilst other studies have found that addition of AG490 protected the heart 
(Hwang et al., 2005, Mascareno et al., 2001), their respective concentrations were 
50 µM and 5 µmol/L, which exceeds the 100nM dose used in this study and by 
others (Lecour et al., 2005b, Suleman et al., 2008, Wang et al., 2004). Hwang et al. 
and Mascareno et al. were also concerned with STAT-5 and STAT-6 activation, and 
not STAT-3 inhibition (Hwang et al., 2005, Mascareno et al., 2001). Lastly, since 
AG490 is an indirect pharmacological inhibitor of STAT-3, the non-specific effects of 
raising drug concentrations cannot be determined (see ‘limitations’). 
 
5.1.2 Possible end effectors of S1P preconditioning 
 
Many researchers have proposed that the anti-apoptotic effect of preconditioning is 
critical in mediating reperfusion injury (Nakamura et al., 2000, Anversa et al., 1998). 
Hence our research has focused on whether S1P can also mediate these 
antiapoptotic effects. 
 
5.1.2.1 BAD 
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Previous research has implicated the increase in antiapoptotic BCL-2 (Ding et al., 
2010), the decrease in proapoptotic BAX (Nakamura et al., 2000) and BAD (Stein et 
al., 2007, Feng et al., 2005, Das et al., 2005). In fact, recent research has suggested 
that BAD is down regulated in response to TNFα preconditioning via the JAK/STAT-3 
pathway (Lecour et al., 2005b). 
 
Our results did not support a down regulation of proapoptotic BAD with S1P 
preconditioning. Such results are in agreement with another paper in which coronary 
effluent from preconditioned hearts induced a preconditioned state in donor hearts 
using the JAK/STAT-3 signalling cascade, but failed to detect a difference in BAD 
activation (Huffman et al., 2008). In contrast, other studies have noted the 
involvement of proapoptotic BAD but have either used different preconditioning 
stimuli such as bradykinin (Feng et al., 2005), resveratrol (Das et al., 2005) and late 
preconditioning (Stein et al., 2007), or have used non-cardiac models such as liver 
(Izuishi et al., 2006, Kulhanek-Heinze et al., 2004, Wang et al., 2008) or neurons 
(Miyawaki et al., 2008). In addition to these differences, activation of BAD was 
thought to have occurred via other signalling pathways including the Akt pathway 
(Das et al., 2005, Izuishi et al., 2006), extracellular signal-regulated kinase (ERK) 
pathway (Wang et al., 2008) and protein kinase A (Kulhanek-Heinze et al., 2004). 
However, our data needs to be interpreted with caution as only two time points were 
considered to measure the phosphorylation of BAD at the onset of reperfusion. 
 
The importance of BAD translocation, in particular to the cytosol and specifically the 
mitochondria, is still postulated in cardiac preconditioning (Murphy, 2004). During 
normal physiological conditions, BAD is phosphorylated and hence bound to 14-3-3 
therefore allowing Bcl-2 to inhibit apoptosis. Once unphosphorylated, apoptosis is 
allowed to proceed with BH123 protein inducing outer membrane permeabilisation of 
the mitochondria (Obexer et al., 2007, Letai et al., 2002). 
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5.1.2.2 FOXO 
 
Very few studies have examined the role of FoxO in ischaemic preconditioning. Of 
these four papers, most have recognised that Akt activation is central to 
phosphorylation and hence inactivation of the proapoptotic effects of FoxO.  
 
Such evidence is provided in neuronal tissue, indicating that hypoxic preconditioning 
can activate Akt to phosphorylate FoxO1, FoxO3a and FoxO4. Interestingly, the 
phosphorylation of these FoxO’s were decreased at 4 hours of reperfusion but 
increased at 14 and 48 hours of reperfusion (Zhan et al., 2010). Similarly, in PC12 
cells (rat pheochromocytoma), ischaemic preconditioning induced phosphorylation of 
Akt and inactivation of GSK3β and FoxO4 (Hillion et al., 2006). Finally, ischaemic 
preconditioning in H11 kinase cardiac specific overexpressing mice resulted in an 
increase in Akt activity to inhibit and prevent the proapoptotic role of GSK3β, FoxO1a 
and BAD (Depre et al., 2006). 
 
Our study did not support a change in phosphorylation status of FoxO at 5 and 15 
minutes of reperfusion from S1P preconditioning. Again, the time point measuring 
FoxO may have been incorrect to measure the activation of FoxO by S1P 
preconditioning. 
 
The importance of FoxO translocation, in particular to the nucleus, can be found from 
ischaemia reperfusion studies and not yet from ischaemic preconditioning studies. 
Whilst our results did not show FoxO translocation as a result of S1P 
preconditioning, ischaemia reperfusion studies have shown that FoxO can 
translocate to the nucleus. The result can be to an beneficial hence an increase in 
manganese superoxide dismutase as seen in Sirt1 mediated cardioprotection (Hsu 
et al., 2010) or activation of GADD45 (a DNA repair target gene) (Brunet et al., 
2004).  
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5.1.3.  Clinical relevance of S1P preconditioning 
 
Pharmacological preconditioning has been evaluated with adenosine (Ross et al., 
2005), nicorandil (Horinaka et al., 2010), ANP (Kitakaze et al., 2007) and recently, 
cyclosporine (Piot et al., 2008). S1P presents a novel therapeutic target to activate 
STAT-3 as part of the SAFE pathway and results in cardioprotection. 
 
5.2. Ischaemic postconditioning confers protection to hearts 
subjected to either regional or global ischaemia via STAT-3 
 
Early data demonstrated the need for STAT-3 activation to result in Akt activation 
and subsequent RISK pathway activation (Goodman et al., 2008). Later, more 
evidence was gathered to support the preferential involvement of STAT-3 in 
ischaemic postconditioning (Lacerda et al., 2009). In fact, some have suggested that 
rather than the cytosolic or nuclear pool of STAT-3 accounting for the protective 
effects of postconditioning, the mitochondrial pool of STAT-3 was far more important 
(Lacerda et al., 2010, Boengler et al., 2010). 
 
Our data has confirmed the protective effect of STAT-3 activation in ischaemic 
postconditioning and indeed, in rat hearts undergoing global ischaemia. This is in 
agreement with previously published reports (You et al., 2011, Goodman et al., 
2008). 
 
The role of STAT-3 as part of the JAK/STAT-3 signalling pathway and its interaction 
with another significant pathway such as RISK is increasingly being explored. Since 
the seminal paper that proposed that the two pathways are distinct but 
interdependent on one another (Lecour et al., 2005b), another author has proposed 
that the JAK/STAT pathway may in fact regulate the RISK pathway (Goodman et al., 
2008). In fact, very recent evidence is in support of this hypothesis, demonstrating 
that with STAT-3 activation, Akt and ERK are activated (Pedretti and Raddatz, 2011, 
Zhuo et al., 2011).  
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Despite the recent knowledge of elucidating how pathways interact with one another, 
further evidence is required to elucidate the role of STAT-3 on the mitochondria 
directly. Many researchers have found that the MPTP channel serves as the 
common end point of any pathway to determine cell survival. Maintaining closure of 
the MPTP channel prevents the release and activation of proapoptotic caspases, 
and activation of 14-3-3 which inactivates proapoptotic enzymes like FoxO and BAD 
(Halestrap et al., 2004, Hausenloy et al., 2009). 
 
The use of regional and global ischaemia models were relevant because both 
models replicate either preconditioning or postconditioning in potentially clinically 
important situations. Those situations which mimic the regional ischaemia model 
include the use of coronary balloon angioplasty as a conditioning mimetic before 
coronary artery bypass surgery (preconditioning) or after a myocardial infarct 
(postconditioning). Furthermore, the situations which mimic the global ischaemia 
model include the use of aortic cross clamping and declamping as a conditioning 
mimetic before cardiac transplant (preconditioning) or, in combination with remote 
postconditioning, the use of a blood pressure cuff to inflate and deflate repetitively 
prior to cardiac surgery (remote preconditioning) (Hausenloy and Yellon, 2008, 
Granfeldt et al., 2009). The latter provides a non-invasive method of inducing a 
conditioning state globally which potentially can have local benefits to the heart as 
well as systemic benefits to other organs such as liver, spleen, gastrointestinal tract 
and kidney (Saxena et al., 2010, Hausenloy and Yellon, 2008). 
 
5.2.1  Clinical relevance of ischaemic postconditioning and STAT-3 
 
Whilst many clinical studies have examined the protective effect of ischaemic 
postconditioning (Staat et al., 2005, Thibault et al., 2008), no studies have clinically 
evaluated the potential success of pharmacologically targeting the JAK/STAT-3 
pathway with pharmacological postconditioning. This study hopes to add to existing 
scientific evidence to the growing knowledge of postconditioning and results in the 
development of novel therapeutic strategies of targeting the JAK/STAT-3 pathway to  
to protect the heart. 
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5.3 Limitations 
 
5.3.1 Time point for western blot tissue collection 
 
Many studies have sampled protein for western blot analysis prior to the index 
ischaemia in preconditioning studies. However, only one study has examined the 
state of protein phosphorylation levels after the index ischaemia (Hausenloy et al., 
2005). Similar to the aforementioned study, we too examined the phosphorylation 
levels of STAT-3 after the index ischaemia despite using a preconditioning stimulus. 
Hence, we are only able to conclude that STAT-3 phosphorylation levels no longer 
have a dichotomy between cytosolic and nuclear fractions following preconditioning 
and reperfusion after the index ischaemia. However what remains unknown is the 
activity of mitochondrial STAT-3 at this time point. Furthermore, because our time 
point is different to the majority of other studies, comparison between our results and 
others must be cautioned. 
 
5.3.1.1. Sample size 
 
Throughout the experiment, numerous data demonstrated a trend in the difference 
amongst groups. Since statistical significance was not reached, it is compelling to 
increase the sample size for each group in order to achieve significance. Conversely, 
given the current small sample size, significant data should be interpreted cautiously 
but generally the p value was small enough to demonstrate that a significant 
difference was observed amongst groups despite the small sample size. 
 
5.3.2. In vivo vs. in vitro studies 
 
S1P has many pleiotrophic effects not restricted to cardiomyocytes or fibroblasts. 
These include S1P mediated effects on the endothelium, vascular smooth muscle, 
platelets and red blood cells (Karliner, 2009, Saba and Hla, 2004). Invariably, use of 
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S1P in vivo rather than in vitro or ex vivo would enable us to account for these 
systemic effects which can impact on the overall outcome. 
 
5.3.3. AG490 and use of knock out mouse model 
 
Pharmacological blockade of the JAK/STAT-3 pathway by AG490 has not always 
lead to consistent results (Mascareno et al., 2001, Negoro et al., 2001). Such 
inconsistencies can be explained because AG490 is a JAK2 inhibitor and hence 
indirectly inhibits STAT-3. Recent creation of stattic in 2006 was a welcomed 
addition to the direct pharmacological blockade of STAT-3 (Schust et al., 2006). 
However, the use of cardiac specific STAT-3 genetic knock-out mice is far better in 
ensuring the blockade of STAT-3 (Smith et al., 2004).  
 
5.4 Future studies 
 
To elucidate the role of STAT-3 in cardioprotection, it would be important to employ 
different models such as cardiac specific genetic knock-out mice for STAT-3 (Smith 
et al., 2004), with or without the use of direct pharmacological blockade with the 
recent development of stattic, a selective inhibitor of tyrosine phosphorylation of 
STAT-3 (Schust et al., 2006) or FLLL32, a derivative of curcumin which specifically 
reduces phosphorylation STAT-3 at its Tyrosine 705 site (Bill et al., 2010). 
 
In addition, the use an in vivo rather than an in vitro model would be of benefit 
because it would include the systemic effects of STAT-3 activation on the 
endothelium (Hilfiker-Kleiner et al., 2005) and allow us to examine the long term 
effects of STAT3 on the myocardium (Haghikia et al., 2011). 
 
With gaining interest in S1P and the sphingolipid pathway, additional 
pharmacological agonists and antagonists are being developed to target S1P directly 
or indirectly. Hence pharmacological agents such as FTY720 (a S1P receptor type 1 
agonist) or VPC 23019 (a competitive antagonist of S1P receptors type 1 and 3) or 
U
ni
ve
rs
ity
 o
f C
ap
e 
To
w
n
 
 
106 
 
dl-threo-dihydrosphingosine (DHS), a competitive inhibitor of sphingosine kinase, 
could be used in the future (Takabe et al., 2008). It would be of interest to delineate 
which receptor is involved in S1P induced cardioprotection against ischaemia 
reperfusion. 
 
There have been proposed challenges to the dogma of STAT-3 signalling (Sehgal, 
2008) citing the existence of a mitochondrial pool of STAT-3 (Wegrzyn et al., 2009), 
which can directly influence mitochondrial function (Lacerda et al., 2010, Boengler et 
al., 2010). Such recent evidence merits further investigation to elucidate if STAT-3 
modulates mitochondrial function in S1P induced cardioprotection. 
 
5.5 Conclusion 
 
Our data demonstrates that S1P preconditioning can protect the heart similar to 
ischaemic preconditioning via activation of STAT-3 as part of the SAFE pathway. 
The pathway is also involved in the cardioprotective effect of ischaemic 
postconditioning. Our data provides a unique therapeutic opportunity to target 
survival against ischaemic reperfusion injuries, especially since S1P forms part of 
high density lipoproteins. Addition of S1P to already existing synthetic HDL may be 
considered as a therapeutic option in the treatment of ischaemic heart disease.  
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preconditioning. 
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pathways in ischaemic postconditioning. 
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ischaemia via STAT-3 activation. 
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cardioprotection is mediated by STAT-3. Journal of Molecular and Cellular 
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